<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79018</article-id><article-id pub-id-type="doi">10.7554/eLife.79018</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Centrally expressed Cav3.2 T-type calcium channel is critical for the initiation and maintenance of neuropathic pain</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-275936"><name><surname>Fayad</surname><given-names>Sophie L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4834-6524</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275937"><name><surname>Ourties</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275938"><name><surname>Le Gac</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275939"><name><surname>Jouffre</surname><given-names>Baptiste</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275940"><name><surname>Lamoine</surname><given-names>Sylvain</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275941"><name><surname>Fruquière</surname><given-names>Antoine</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275942"><name><surname>Laffray</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275943"><name><surname>Gasmi</surname><given-names>Laila</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-50192"><name><surname>Cauli</surname><given-names>Bruno</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1471-4621</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275944"><name><surname>Mallet</surname><given-names>Christophe</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0873-6763</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35877"><name><surname>Bourinet</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275945"><name><surname>Bessaih</surname><given-names>Thomas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0764-7731</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-274836"><name><surname>Lambert</surname><given-names>Régis C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8972-1151</contrib-id><email>regis.lambert@sorbonne-universite.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-275946"><name><surname>Leresche</surname><given-names>Nathalie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6705-9769</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine – Institut de Biologie Paris Seine</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01a8ajp46</institution-id><institution>Université Clermont Auvergne, Inserm, U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur</institution></institution-wrap><addr-line><named-content content-type="city">Clermont-Ferrand</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution>ANALGESIA Institute, Faculty of Medicine</institution><addr-line><named-content content-type="city">Clermont-Ferrand</named-content></addr-line><country>France</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043wmc583</institution-id><institution>Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM</institution></institution-wrap><addr-line><named-content content-type="city">Montpellier</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Westbrook</surname><given-names>Gary L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/009avj582</institution-id><institution>Oregon Health &amp; Science University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Westbrook</surname><given-names>Gary L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/009avj582</institution-id><institution>Oregon Health &amp; Science University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>23</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e79018</elocation-id><history><date date-type="received" iso-8601-date="2022-03-28"><day>28</day><month>03</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-11-22"><day>22</day><month>11</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-04-29"><day>29</day><month>04</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.04.27.489708"/></event></pub-history><permissions><copyright-statement>© 2022, Fayad et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Fayad et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79018-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-79018-figures-v2.pdf"/><abstract><p>Cav3.2 T-type calcium channel is a major molecular actor of neuropathic pain in peripheral sensory neurons, but its involvement at the supraspinal level is almost unknown. In the anterior pretectum (APT), a hub of connectivity of the somatosensory system involved in pain perception, we show that Cav3.2 channels are expressed in a subpopulation of GABAergic neurons coexpressing parvalbumin (PV). In these PV-expressing neurons, Cav3.2 channels contribute to a high-frequency-bursting activity, which is increased in the spared nerve injury model of neuropathy. Specific deletion of Cav3.2 channels in APT neurons reduced both the initiation and maintenance of mechanical and cold allodynia. These data are a direct demonstration that centrally expressed Cav3.2 channels also play a fundamental role in pain pathophysiology.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>anterior pretectum</kwd><kwd>GABAergic neurons</kwd><kwd>voltage-dependent calcium channels</kwd><kwd>spared nerve injury model</kwd><kwd>parvalbumin</kwd><kwd>burst</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-15-CE16-0012-03</award-id><principal-award-recipient><name><surname>Bourinet</surname><given-names>Emmanuel</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Specific deletion of Cav3.2 channels in anterior pretectal neurons reduced mechanical and cold allodynia, pointing to Cav3.2 channels as prime targets to develop innovative analgesic pharmacology that will not only act at the peripheral level but also in central structures.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Neuropathic pain is a wide spread condition with severe side effects and limited effectiveness of available treatments. Such public health issue stimulates the search for putative molecular targets, among which ion channels expressed in pain pathways are prime candidates (<xref ref-type="bibr" rid="bib2">Bennett and Woods, 2014</xref>; <xref ref-type="bibr" rid="bib5">Bourinet et al., 2016</xref>). In particular, at the peripheral level, it was shown that the Cav3.2 isoform of the low-threshold T-type calcium channels (T channels) is overexpressed in dorsal root ganglion (DRG) neurons after chronic constrictive injury of the sciatic nerve (<xref ref-type="bibr" rid="bib22">Jagodic et al., 2008</xref>). Silencing the Cav3.2 isoform using intrathecal antisense oligonucleotides administration had profound antihyperalgesic and antiallodynic effects in various neuropathic pain models (<xref ref-type="bibr" rid="bib4">Bourinet et al., 2005</xref>; <xref ref-type="bibr" rid="bib38">Messinger et al., 2009</xref>; <xref ref-type="bibr" rid="bib49">Takahashi et al., 2010</xref>). Furthermore, specific knockout (KO) of Cav3.2 in a subtype of DRG neurons alleviated both mechanical and cold allodynia produced by spared nerve injury (SNI) (<xref ref-type="bibr" rid="bib17">François et al., 2015</xref>). While these data converge toward a critical role for peripherally expressed Cav3.2 in neuropathic pain, very little is known on a putative pronociceptive role of centrally expressed Cav3.2.</p><p>In the central nervous system, in situ hybridization studies revealed strong expression of the Cav3.2 transcript in scattered neurons of the anterior pretectum (APT) (<xref ref-type="bibr" rid="bib50">Talley et al., 1999</xref>), a crossroads of ascending and descending connectivity of the somatosensory system (<xref ref-type="bibr" rid="bib42">Rees and Roberts, 1993</xref>). The idea that APT plays a key role in nociception dates back to the 1980s, when it was shown that brief low-intensity electrical or chemical stimulations of this nucleus elicited antinociception (<xref ref-type="bibr" rid="bib41">Prado and Roberts, 1985</xref>; <xref ref-type="bibr" rid="bib42">Rees and Roberts, 1993</xref>; <xref ref-type="bibr" rid="bib44">Roberts and Rees, 1986</xref>). Involvement of APT in chronic pain was later confirmed by lesions and stimulations performed in different rodent pain models (<xref ref-type="bibr" rid="bib43">Rees et al., 1995</xref>; <xref ref-type="bibr" rid="bib45">Rossaneis et al., 2014</xref>; <xref ref-type="bibr" rid="bib46">Rossaneis and Prado, 2015</xref>; <xref ref-type="bibr" rid="bib55">Villarreal et al., 2004</xref>; <xref ref-type="bibr" rid="bib54">Villarreal et al., 2003</xref>). To date the excitability of this structure has been little studied (<xref ref-type="bibr" rid="bib3">Bokor et al., 2005</xref>) but an increase firing of fast-bursting neurons was reported in a model of central pain syndrome (<xref ref-type="bibr" rid="bib39">Murray et al., 2010</xref>). Since T channels are involved in burst generation in numerous neuronal populations (<xref ref-type="bibr" rid="bib29">Lambert et al., 2014</xref>), we took advantage of a murine model that allows the identification of the Cav3.2 channels and their conditional deletion in specific area (<xref ref-type="bibr" rid="bib17">François et al., 2015</xref>) to investigate their role in shaping APT neuron excitability and the initiation and maintenance of neuropathic pain.</p><p>We show that (1) Cav3.2 channels are specifically expressed in GABAergic parvalbumin (PV)-expressing neurons of the APT; (2) bursting activity of these neurons is increased in the SNI model of neuropathic pain; (3) the Cav3.2 channel contribution to the bursting activity of the PV-expressing neurons is enhanced in the SNI model, and (4) their specific deletion in the APT significantly reduces both the initiation and maintenance of neuropathic mechanical and cold allodynia in the SNI model.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Cav3.2 channels are expressed in PV-positive neurons of the APT</title><p>To examine Cav3.2 expression in APT neurons, we used the Cav3.2-eGFPflox (KI) mouse line, in which an ecliptic GFP tag is expressed in the extracellular loop of the Cav3.2 channel (<xref ref-type="bibr" rid="bib17">François et al., 2015</xref>). Anti-GFP labeling revealed the expression of the Cav3.2-GFP fusion protein in a scattered subpopulation of neurons from naïve KI animals (<xref ref-type="fig" rid="fig1">Figure 1A, B</xref>). Co-labeling of GFP- and NeuN-positive cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) showed that 20.0 ± 3.9% of the APT cells express the Cav3.2-GFP channel. Since a previous study performed by <xref ref-type="bibr" rid="bib3">Bokor et al., 2005</xref> in rats suggests that APT fast-bursting neurons strongly expressed PV, the overlap between Cav3.2-GFP+ and PV-positive (PV+) populations was estimated using GFP and PV co-labelings (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). We thus determined that 87.1 ± 10.0% of Cav3.2-GFP+ cells coexpress PV. Conversely 91.8 ± 5.6% of PV+ cells coexpress Cav3.2-GFP confirming the overlap between the Cav3.2-GFP+ and PV+ cell populations (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Coexpression of Cav3.2 and parvalbumin (PV) in APT neurons.</title><p>Left panels: Cav3.2-GFP immunostaining on a parasagittal (<bold>A</bold>) and a coronal (<bold>B</bold>) section of KI mice brains. Right panels: corresponding Mouse Brain Atlas slides from Paxinos and Franklin (parasagittal: 1.08 mm lateral from Bregma; coronal: 2.8 mm posterior from Bregma). APT: anterior pretectum; Cx: cortex; Hpc: hippocampus; nRT: nucleus reticularis thalami; PAG: periaqueductal grey; SC: superior colliculi; SNc: substantia nigra pars compacta; ZI: zona incerta. (<bold>C</bold>) Confocal microscopy images of a coronal KI mouse brain section of the APT with GFP (green) and PV (red) co-labeling. Scale bar: 100 µm.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Quantification of Cav3.2-GFP- and parvalbumin (PV)-expressing neurons.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79018-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79018-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Anterior pretectum (APT) neurons expressing GFP and parvalbumin (PV).</title><p>Confocal microscopy images of the co-labelings performed in the APT to estimate the proportion of GFP neurons (A: GFP in green, NeuN in red) and PV neurons (B: PV in green, NeuN in red) and the overlap between these populations (C: GFP in green, PV in red). Scale bar: 30 µm. (<bold>D</bold>) Diagram representing the percentage of neurons expressing GFP and PV in the APT.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79018-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Burst firing of PV+ neurons is increased in SNI animals</title><p>Based on this overlap, we next investigated the firing activity of this subpopulation in anesthetized animals, using PV-Cre:Ai32 mice that selectively express channelrhodopsin-2 (ChR-2) in PV+ neurons. One to two tetrodes were lowered to the APT in the contralateral side of the sham or SNI surgeries to record multiunit spiking activity alongside with EEG signal (<xref ref-type="fig" rid="fig2">Figure 2A, B</xref>). Spike-sorting algorithms were further used to isolate one to three single-unit spiking activities per tetrode (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). In sham mice using Photo-assisted Identification of Neuronal Population (PINP; <xref ref-type="bibr" rid="bib35">Lima et al., 2009</xref>), PV+ single units were identified by the reliable short latency (5.3 ± 2.4 ms) evoked response consisting of one or more spikes elicited by each 470-nm blue-light pulse (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). As shown in <xref ref-type="fig" rid="fig2">Figure 2E</xref>, 77% (<italic>n</italic> = 21) of the units had a peak around 2–5 ms in their autocorrelogram, indicating their ability to elicit bursts, and are thus referred to as ‘bursting cells’. Their mean firing rate was 8.4 ± 2.8 Hz and bursts, consisting of 2–3 action potentials (mean: 2.9 ± 0.6) occurring at 252 ± 18.7 Hz, represented 13.7 ± 6.8% of the total number of spikes. The six remaining units showed a flat distribution of interspike intervals (ISIs) with a mean firing rate of 4.4 ± 1.7 Hz, and are thus referred to as ‘regular cells’ (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Impact of spared nerve injury (SNI) in PV+ anterior pretectum (APT) neurons.</title><p>(<bold>A</bold>) Example image of a DiI track left by a recording electrode inserted into the APT. Red: DiI. (<bold>B</bold>) Raw signals from the four wires of a tetrode. Bottom trace shows the simultaneous EEG recording. (<bold>C</bold>) Left panel: example of a tetrode recording where two units were isolated. All detected action potentials are plotted as their waveform’s amplitude from channel 1 versus the amplitude of their waveform’s valley from channel 1 (in arbitrary units, A.U.). Using this feature space arrangement, two single-unit clusters were isolated (in red and yellow). Right panel: superimposed color-coded action potential waveforms captured by each recording site of the tetrode are shown for the two identified single units (the polarity of the signals is inverted). (<bold>D</bold>) Example of peristimulus time histograms illustrating spiking response to optogenetic stimulation (10 ms long, represented in blue) over 100 trials of a unit categorized into the PV+ category. (<bold>E</bold>) Autocorrelogram of recorded single unit for one example cell. 1 ms bins were used. Red dotted lines represent 99% confidence intervals. (<bold>F</bold>) Scatter dot plots of mean firing rate (left panel), proportion of spikes within a burst (middle panel), and mean spike frequency within a burst (right panel) for fast-bursting APT cells recorded in sham (<italic>n</italic> = 21 cells, 5 animals) and SNI (<italic>n</italic> = 18 cells, 4 animals) mice. p values for statistical comparisons were obtained using Wilcoxon sum rank test.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Firing properties of parvalbumin (PV)-expressing neurons after spared nerve injury (SNI).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79018-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79018-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Anterior pretectum (APT) regular spiking neurons.</title><p>(<bold>A</bold>) Example of peristimulus time histograms illustrating spiking response to optogenetic stimulation (10 ms long, represented in blue) over 100 trials of a unit categorized into the PV+ category. (<bold>B</bold>) Autocorrelogram of recorded single unit for one example cells. 1 ms bins were used. Red dotted lines represent 99% confidence intervals.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Firing properties of PV+ regular spiking neurons.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79018-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79018-fig2-figsupp1-v2.tif"/></fig></fig-group><p>The spiking properties of PV+ neurons were next compared between sham and SNI animals. Although the proportion of bursting cells was similar in the two conditions (77% vs. 75%, respectively), we observed a significant increase upon SNI, in the mean firing rate (<xref ref-type="fig" rid="fig2">Figure 2F</xref>; left panel; 11.4 ± 3.2 Hz; Wilcoxon sum rank test; p = 0.0036), in the proportion of spikes belonging to a burst (<xref ref-type="fig" rid="fig2">Figure 2F</xref>; middle panel; 20.9 ± 7.8%; Wilcoxon sum rank test; p = 0039), and in the mean spike frequency within a burst (<xref ref-type="fig" rid="fig2">Figure 2F</xref>; right panel; 270.6 ± 20.6 Hz; Wilcoxon sum rank test; p = 0.01). No difference was observed in the mean firing rates of regular cells for which the mean spike frequency in SNI animals was 6.7 ± 3.9 Hz (Wilcoxon sum rank test; p = 0.35).</p><p>We therefore concluded that most of the PV+ and Cav3.2+ neurons of the APT are bursting neurons and that their bursting activities are enhanced in the neuropathic pain state.</p></sec><sec id="s2-3"><title>Contribution of Cav3.2 channels to PV+ APT neuron excitability</title><p>In order to estimate how Cav3.2 channels contribute to the firing activity observed in vivo, we characterized the excitability of the PV+ neurons using whole-cell patch-clamp recordings combined with biocytin labeling in slices obtained from PV-Cre:AI14 mice that express TdTomato in PV+ neurons. In response to a pulse of depolarizing current all APT fluorescent neurons behaved as fast-spiking neurons with a high discharge rate (mean maximal firing rate upon depolarizing current of increasing amplitude: 214 ± 112 Hz, <italic>n</italic> = 60, <xref ref-type="fig" rid="fig3">Figure 3A</xref>). In response to the injection of a hyperpolarizing current step (peak hyperpolarization ranging from −95 to −105 mV), common features were a large amplitude sag (17 ± 6 mV, <italic>n</italic> = 62), indicating the presence of an Ih current, and a rebound depolarization that underlie a burst of high-frequency action potentials in 57 out of 62 recorded neurons (mean number of spikes 7 ± 4, <italic>n</italic> = 57).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>PV+ neurons expressing Cav3.2 channels are GABAergic fast-spiking neurons.</title><p>(<bold>A</bold>) Left image: recorded neuron filled with biocytin (green). Neurons in red are nonrecorded PV+ neurons. Middle traces: depolarizing current injection evokes characteristic fast-spiking activity. Hyperpolarizing current injection evoked a pronounced sag and a rebound high-firing burst upon repolarization. Inset: enlargement of the bursting activity. Right graph: number of spikes evoked by 1 s long depolarizing current injection of increasing amplitudes. (<bold>B</bold>) Typical example of activities and scRT-PCR products observed in a PV+ neuron. Note the expression of the Cav3.2 channel in the GAD65- and 67-positive neuron.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Excitability properties of PV+ neurons.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79018-fig3-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Original file of the full raw unedited gel shown in <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79018-fig3-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Molecular profile of PV+ neurons.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79018-fig3-data3-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79018-fig3-v2.tif"/></fig><p>Transcriptomic characterization of PV+ neurons was further performed by combining patch-clamp recordings and multiplex single-cell reverse transcriptase PCR (scRT-PCR; <xref ref-type="fig" rid="fig3">Figure 3B</xref>). All neurons expressed PV transcript and among them, 73.9% expressed GAD65 and/or GAD67 mRNA (<italic>n</italic> = 17/23), the remaining ones (<italic>n</italic> = 6/23) expressed Vglut2 mRNA. Importantly the Cav3.2 transcript was present in 13 out of the 17 GABAergic neurons but never detected in glutamatergic neurons. mRNA of the two other Cav3 isoforms was also detected, albeit less frequently (Cav3.1: <italic>n</italic> = 10/13; Cav3.3: <italic>n</italic> = 3/13) in GABAergic neurons coexpressing Cav3.2 and in glutamatergic neurons (Cav3.1: <italic>n</italic> = 5/6; Cav3.3: <italic>n</italic> = 1/6). These results strongly suggest that PV+ neurons expressing the Cav3.2 channels are fast-spiking GABAergic neurons.</p><p>We then investigated whether the Cav3.2 isoform contributed to the rebound depolarization and its associated high-frequency burst firing. As shown in <xref ref-type="fig" rid="fig4">Figure 4A, C</xref>, application of 100 µM Ni<sup>2+</sup>, a concentration that specifically blocks Cav3.2 channels (<xref ref-type="bibr" rid="bib32">Lee et al., 1999</xref>), significantly decreased the number of action potentials (ctr: 7.0 ± 3.1/Ni<sup>2+</sup>: 3.8 ± 2.8; <italic>n</italic> = 8; Wilcoxon signed rank test p = 0.0039), the firing frequency (min ISI: ctr: 3.4 ± 0.9 ms/Ni<sup>2+</sup>: 6.6 ± 4.0 ms; <italic>n</italic> = 6; Wilcoxon signed rank test p = 0.0156) and the amplitude of the underlying depolarization measured in the presence of TTX (ctr: 13.6 ± 5.2/Ni<sup>2+</sup>: 10.8 ± 6.1 mV; <italic>n</italic> = 10; Wilcoxon signed rank test p = 0.0029). A block of all T channels isoforms using the pan antagonist TTA-P2 produced an even stronger decrease of the rebound activity, as expected from the results of the scRT-PCR (<xref ref-type="fig" rid="fig4">Figure 4B, C</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Cav3.2 channel contribution to the bursting activity of PV+ neurons is enhanced in spared nerve injury (SNI) mice.</title><p>(<bold>A</bold>) Effect of 100 µM Ni<sup>2+</sup> applications on the number of spikes (left graph, <italic>n</italic> = 8) and the minimal interspike intervals (ISIs; right graph, <italic>n</italic> = 6) of the rebound bursts. Typical examples of these pharmacological effects are shown on the right. (<bold>B</bold>) Effect of 1 µM TTAP2 applications on the number of spikes (left graph, <italic>n</italic> = 11) and the minimal ISIs (right graph, <italic>n</italic> = 7) of the rebound bursts. Typical examples of these pharmacological effects are shown on the right. (<bold>C</bold>) Effect of 100 µM Ni<sup>2+</sup> (left graph, <italic>n</italic> = 10) and 1 µM TTAP2 (right graph, <italic>n</italic> = 12) applications on the amplitude of the rebound depolarization observed in the presence of 0.5 µM TTX. A typical example is presented in superimposed traces presented on the right. (<bold>D</bold>) The two left graphs compare the maximal number of spikes of the rebound bursts evoked in neurons of sham-operated and SNI mice in control condition (<italic>n</italic> = 12 and 15, respectively) and after application of 100 µM Ni<sup>2+</sup> (<italic>n</italic> = 8 and 9, respectively). The effects of Ni<sup>2+</sup> application on each neuron are presented in the two right graphs (<italic>n</italic> = 8 and 9 for sham and SNI, respectively). A, B, C, D right graphs: Wilcoxon signed rank test; D left graphs: Wilcoxon sum rank test. ***p &lt; 0.001 ; **p: 0.001 &lt; p &lt; 0.01 ; *0.01 &lt; p &lt; 0.05.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Ni and TTA effects on burst properties of PV+ neurons.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79018-fig4-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Ni and TTA effects on the rebound depolarization in PV+ neurons.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79018-fig4-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Burst properties of PV+ neurons in slices from sham and spared nerve injury (SNI) mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79018-fig4-data3-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79018-fig4-v2.tif"/></fig><p>Since in vivo recordings showed an increased in bursting activities of PV+ neurons in SNI mice compared to sham control mice, we further compared the rebound bursts in slices from sham-operated and SNI mice. As shown in <xref ref-type="fig" rid="fig4">Figure 4D</xref>, the distribution of the maximal number of spikes of rebound bursts evoked in PV+ neurons is shifted toward larger values in SNI compared to sham-operated mice (mean maximal number of spikes: 9.1 ± 2.3, <italic>n</italic> = 15, 6.3 ± 1.8, <italic>n</italic> = 12, for SNI and sham, respectively; Wilcoxon sum rank test p = 0.0012). Importantly, this difference in distribution is suppressed when Cav3.2 channels are blocked with 100 µM Ni<sup>2+</sup>, strongly suggesting that these channels participate in the increased rebound burst activities observed in SNI mice.</p></sec><sec id="s2-4"><title>Impact of Cav3.2 channel deletion in APT on mechanical and cold sensitivity</title><p>The Cav3.2-eGFPflox mouse line not only allows the visualization of Cav3.2 channels but also their deletion (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Considering the in vitro results suggesting that Cav3.2 channels may contribute to the increased burst activities observed in PV+ neurons of SNI mice recorded in vivo, we investigated whether local deletion of these channels in APT could alleviate the neuropathic phenotype. Mechanical and cold allodynia, the cardinal somatosensory phenotypes typical of the SNI model were thus compared between mice that were bilaterally injected in the APT with either an AAV-Cre-mCherry virus (APT-KO mice; <italic>n</italic> = 6 males and 6 females) or an AAV-mCherry (control KI mice; <italic>n</italic> = 7 males and 9 females; <xref ref-type="fig" rid="fig5">Figure 5A</xref>) and then 2 weeks later subjected to the SNI surgery to induce the neuropathy. Mechanical sensitivity was assessed by measuring paw withdrawal threshold (PWT) on the operated hindpaw using Von Frey filaments (<xref ref-type="bibr" rid="bib9">Chaplan et al., 1994</xref>). Prior to SNI procedure, two baseline measurements were performed, before and 2 weeks after viral injections. No significant differences were found in the PWT between these two measurements within each group or between KI and APT-KO mice, indicating that neither the viral injection by itself, nor the local deletion of Cav3.2 impacts acute mechanical sensitivity. Baseline measurements were therefore averaged within each group (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). A statistically significant decrease in PWT was observed in KI mice following SNI from day 14 postsurgery, confirming the development of a mechanical allodynia. Importantly, this decrease was strongly attenuated in APT-KO compared to KI mice (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). This difference between APT-KO mice and their KI littermates was not due to motor or coordination deficits (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C, D</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Cav3.2 preventive and therapeutic knockout in the anterior pretectum (APT) alleviates neuropathy induced by spared nerve injury (SNI).</title><p>(<bold>A</bold>) Confocal microscopy images of GFP (green) and mCherry (red) co-labeling in the APT of KI-Cav3.2-GFP (Control) mice and KO-Cav3.2-APT (KO) bilaterally injected in the APT with AAV8-hSyn-mCherry and AAV8-hSyn-mCherry-CRE virus, respectively, and further tested for mechanical and cold sensitivity. Scale bar: 100 µm. Neuropathic behaviors were tested in male (dashed lines) and female (solid lines) mice with preventive (<bold>B, D</bold>) and therapeutic (<bold>C, E</bold>) KO of Cav3.2 in the APT (orange, ■), and in control KI mice (green, ●). (<bold>B, C</bold>) Mechanical sensitivity was assessed by measuring paw withdrawal thresholds (PWTs) in response to Von Frey filaments stimulations using the up-and-down method. (<bold>D, E</bold>) Cold sensitivity was assessed by measuring the paw withdrawal latency in response to immersion in 18°C water. For preventive KO (<bold>B, D</bold>) mice were tested prior to the SNI (BL) and once a week during the 6 subsequent weeks (days 14–48). For therapeutic KO (<bold>C, E</bold>) mechanical and cold sensitivity were assessed before (BL) and 14 days after SNI (SNI), and tested during several weeks following the subsequent viral injections (days 14–56 after viral injection). (<bold>B–E</bold>) Wilcoxon sum rank test for female KO versus KI and male KO versus KI comparison at each time point. ++++ : p &lt; 0.0001, +++ or ▲▲▲: 0.0001 &lt; p &lt; 0.001, ++ or ▲▲: 0.001 &lt; p &lt; 0.01, + or ▲: 0.01 &lt; p &lt; 0.05 (males: +; females: ▲).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Characterization of the effect of APT-Cav3.2 preventive or curative knockout on neuropathic pain induced by spared nerve injury (SNI).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79018-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79018-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Preventive Cav3.2 knockout in the anterior pretectum (APT) has no impact on motor coordination and spontaneous locomotion.</title><p>(<bold>A</bold>) Confocal microscopy images of GFP labeling (green) and mCherry expression (red) in the APT of a KI mouse unilaterally injected with AAV8-hSyn-Cre-mCherry virus (up panel: injected hemisphere; down panel: noninjected hemisphere). Scale bar: 100 µm. Note the drastic reduction in the number of GFP+ neurons observed 2 weeks post viral injection in the injected hemisphere. (<bold>B–D</bold>) Motor coordination and spontaneous locomotion assessed in control KI mice (green, ●) and mice with preventive APT-Cav3.2 KO (orange, ■) subjected to spared nerve injury (SNI). (<bold>B</bold>) Control of the development of mechanical allodynia in male (dashed lines) and female (solid lines) mice. Note that as for the cohorts presented in <xref ref-type="fig" rid="fig5">Figure 5</xref>, preventive Cav3.2 KO reduced allodynia. Wilcoxon sum rank test for female KO versus KI and male KO versus KI comparison at each time point. +++ or ▲▲▲: 0.0001 &lt; p &lt; 0.001, ▲▲: 0.001 &lt; p &lt; 0.01, +: 0.01 &lt; p &lt; 0.05 (males: +; females: ▲). (<bold>C</bold>) Latency to fall from an accelerating rotarod wheel (0–16 rpm over 3 min) was measured in males (dashed bars) and females (solid bars), before (BL) and after (day 21) SNI surgery. No statistical differences were detected between groups and before and after SNI surgery within a group using Wilcoxon sum rank test and Wilcoxon signed rank test, respectively. (<bold>D</bold>) The number of quarter turns was detected in a circular corridor over 120 min, measured in males (dashed bars) and females (solid bars), 21 days after SNI surgery. No significant differences were detected between groups using the Wilcoxon sum rank test.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Characterization of preventive APT-Cav3.2 knockout effect on mechanical sensitivity and locomotion.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79018-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79018-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Cold sensitivity was also assessed using the paw immersion test (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). While KI mice showed a decrease in withdraw latency after SNI when the operated paw was immersed in a water bath at 18°, indicating the development of a cold allodynia, this phenotype was abolished in the preventive APT-KO mice. Altogether, these results clearly indicate that APT-Cav3.2 channels contribute to the initiation of mechanical and cold allodynia characterizing the SNI model in both male and female mice.</p><p>We next investigated whether these allodynic SNI features could be reversed by a therapeutic KO strategy of APT-Cav3.2. We thus injected the Cre-expressing virus 2 weeks after surgery, when allodynic symptoms reach their peak. Both mechanical and cold allodynia were rapidly rescued since tactile threshold lowering was drastically reduced (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) and paw withdrawal latencies returned to preoperative baseline values (<xref ref-type="fig" rid="fig5">Figure 5E</xref>).</p><p>Altogether, these results show that Cav3.2 expressed in the APT is not only involved in the initiation but also in the maintenance of neuropathic phenotype in the SNI model.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We showed that deletion of Cav3.2 channels expressed in a GABAergic and PV-expressing subpopulation of APT neurons leads to an antiallodynic effect in the SNI neuropathic pain model.</p><p>Our in vitro data indicate that 92% of APT-PV+ neurons are able to discharge bursts of action potentials at high frequency underpinned by a rebound large transient depolarization due to the activation of T channels. In contrast to the well-recognized role played by the Cav3.1 and 3.3 isoforms of the T channels (<xref ref-type="bibr" rid="bib27">Kim et al., 2001</xref>; <xref ref-type="bibr" rid="bib33">Lee et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Pellegrini et al., 2016</xref>), little evidences exist for the involvement of the Cav3.2 isoform in burst generation in the central nervous system (<xref ref-type="bibr" rid="bib7">Candelas et al., 2019</xref>; <xref ref-type="bibr" rid="bib14">Dumenieu et al., 2018</xref>). Here, the specific blockade of this isoform greatly reduced the amplitude of the depolarization underlying burst generation and decreased the number and frequency of action potentials within a burst. Therefore, although our transcriptomic and pharmacological results suggest that APT-PV+ GABAergic neurons express multiple isoforms of the T channels, we demonstrate that the Cav3.2 isoform has an essential contribution to the bursting behavior in this subpopulation of APT neurons and its increase in SNI mice.</p><p>Available data about the excitability of APT neurons are very limited. <xref ref-type="bibr" rid="bib3">Bokor et al., 2005</xref> reported a heterogeneous firing pattern in rat APT neurons with about 25% of them presenting high-frequency discharges. Although tested on only three neurons, these fast-bursting neurons were described as strongly expressing PV. Deciphering the roles of a structure that displays such heterogeneity clearly requires recordings of identified neuronal subpopulation. The use of the PINP method allowed us to perform such specific characterization and our in vivo recordings of APT-PV+ neurons showed that 77% of these neurons discharge in bursts with a clear enhancement of bursting activity in SNI mice. Investigating changes in neuronal spiking activity in spinal-lesioned rats, <xref ref-type="bibr" rid="bib39">Murray et al., 2010</xref> also described an increased firing rate of APT neurons with a higher percentage of neurons exhibiting at least one burst compared with sham-operated controls. The increase in bursting behavior reported here was more pronounced than in <xref ref-type="bibr" rid="bib39">Murray et al., 2010</xref> as not only the number of bursts but also the number of spikes and their frequency were enhanced indicating a profound change in this class of APT neurons in neuropathic condition. This disparity likely stems from our ability to record an identified subpopulation of APT neurons, although a difference between neuropathic models cannot be excluded. When considering other brain structures, modifications of high-frequency-bursting activities in pain condition have been reported in human, as well as in various experimental models, and this is particularly well documented in the thalamocortical system. In awake patients with neurogenic pain, recordings from thalamic neurons show an increase in the occurrence of high-frequency bursts (<xref ref-type="bibr" rid="bib23">Jeanmonod et al., 1996</xref>; <xref ref-type="bibr" rid="bib34">Lenz et al., 1989</xref>; <xref ref-type="bibr" rid="bib36">Llinás et al., 1999</xref>). Similar higher proportions of bursting neurons have been reported in ventralis postero-lateralis thalamic neurons following contusive spinal cord lesions in rats (<xref ref-type="bibr" rid="bib19">Gerke et al., 2003</xref>) and monkeys (<xref ref-type="bibr" rid="bib56">Weng et al., 2000</xref>). Furthermore, in the same thalamic nucleus, an increase in the frequency of T-channel-dependent bursts was reported following induction of visceral pain in mice (<xref ref-type="bibr" rid="bib28">Kim et al., 2003</xref>).</p><p>The increased burst firing in APT-PV+ neurons in neuropathic condition prompted us to investigate whether Cav3.2 channels may contribute to this phenotype. Our behavioral analysis firstly showed that removing Cav3.2 specifically from APT-PV+ neurons strongly reduced mechanical and cold allodynia evoked by SNI. Furthermore, removing the Cav3.2 channels when the SNI effects were fully developed rescues the different allodynic symptoms indicating that Cav3.2 channels not only contribute to the development but also to the maintenance of the pain phenotype and strongly suggests their direct electrogenic implication in sustaining allodynia. Since these effects were observed on both male and female mice, the Cav3.2-dependent modification in APT-PV+ neurons activities sustaining allodynia is not sex specific, unlike what was recently reported for layer five PV+ neurons in the prelimbic region of the medial prefrontal cortex using the same neuropathic model (<xref ref-type="bibr" rid="bib24">Jones and Sheets, 2020</xref>). Such lack of sex specificity suggests that this mechanism is a fundamental component of chronic pain processes.</p><p>Comparing the pain phenotypes of wild-type and global Cav3.2<sup>−/−</sup> mice, <xref ref-type="bibr" rid="bib11">Choi et al., 2007</xref> reported reduced sensitivity to acute pain in KO mice but no change in the overall development of neuropathic pain. However, at the peripheral level, multiple data point toward Cav3.2 as a main actor in acute and chronic pain (<xref ref-type="bibr" rid="bib5">Bourinet et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Bourinet et al., 2005</xref>; <xref ref-type="bibr" rid="bib17">François et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Jagodic et al., 2008</xref>; <xref ref-type="bibr" rid="bib38">Messinger et al., 2009</xref>; <xref ref-type="bibr" rid="bib49">Takahashi et al., 2010</xref>) suggesting a possible compensatory phenomenon in condition of complete channel deletion. At the supraspinal levels, very little is known. In the chronic constriction injury model, an increase in Cav3.2 mRNA was observed in the anterior cingulate cortex and local injection of NNC 55-0396, a poorly selective T-channel antagonist (<xref ref-type="bibr" rid="bib21">Huang et al., 2004</xref>; <xref ref-type="bibr" rid="bib47">Schäfer et al., 2016</xref>), partially relieved allodynia (<xref ref-type="bibr" rid="bib48">Shen et al., 2015</xref>). Using various poorly specific T-channel antagonists, <xref ref-type="bibr" rid="bib10">Chen et al., 2010</xref> showed a T-channel-dependent activation of ERK in the paraventricular thalamus following acid-induced chronic muscle pain that was abolished in Cav3.2<sup>−/−</sup> mice. Furthermore, intracerebroventricular injection of the specific antagonist of the three T-channel isotypes, TTA-A2, induced analgesia blunting the effect of paracetamol, the most widely used remedy to treat mild pain, an effect also abolished in Cav3.2<sup>−/−</sup> mice (<xref ref-type="bibr" rid="bib26">Kerckhove et al., 2014</xref>). However, such experiments only suggested a central pronociceptive role of Cav3.2 channels. Our results, showing that local deletion of Cav3.2 channels in 20% of the APT neurons drastically reduced allodynia, provide direct evidence of the involvement of central Cav3.2 channels in neuropathic pain.</p><p>Functionally, as APT-PV+ neurons project to the high-order somatosensory thalamic nucleus, posterior nucleus (PO) (<xref ref-type="bibr" rid="bib3">Bokor et al., 2005</xref>; <xref ref-type="bibr" rid="bib20">Giber et al., 2008</xref>), this antiallodynic effect could be a consequence of the direct involvement of this neuronal population in processing nociceptive afferents from the periphery. However, the net effect of the increased bursting activity of APT-PV+ GABAergic neurons on the PO activity under neuropathic conditions is difficult to predict. Although they account for only a small percentage of GABAergic projections impinging on zona incerta (ZI) (<xref ref-type="bibr" rid="bib20">Giber et al., 2008</xref>), APT PV+ neurons project to the ZI, which in turn inhibit thalamic neurons (<xref ref-type="bibr" rid="bib1">Barthó et al., 2002</xref>; <xref ref-type="bibr" rid="bib31">Lavallée et al., 2005</xref>). Their increased bursting activity may therefore mediate disinhibition of PO neurons by silencing their ZI targets, while conversely mediating direct monosynaptic inhibition of PO neurons. Functionally, however, these two effects may not be opposed, as the impact of inhibitory input on thalamic neurons may result in a change in firing mode rather than in a clear decrease in firing. Indeed, PO neurons, which highly express Cav3.1 T channels (<xref ref-type="bibr" rid="bib50">Talley et al., 1999</xref>), are prone to generate rebound burst firing after transient hyperpolarization due to strong IPSP bursts originating from the APT neurons as shown in vitro by <xref ref-type="bibr" rid="bib3">Bokor et al., 2005</xref>. However, <xref ref-type="bibr" rid="bib37">Masri et al., 2009</xref> reported an increase in firing of the PO neurons but no change in their bursting activity in spinal-lesioned rats, but the recordings were restricted to a localized area of PO containing neurons that receive convergent inputs from both hind paw and vibrissae pad. Therefore, given the potential functional and anatomical regionalization of the PO (<xref ref-type="bibr" rid="bib15">El-Boustani et al., 2020</xref>), determining the net effect of PV+ APT neuron activity on the thalamic neurons will required further in vivo recordings performed in their specific projection area.</p><p>Finally, anatomical and functional investigation of the APT described descending pathways impinging through complex routes on various spinal cord neuronal types and involved in pain processing (<xref ref-type="bibr" rid="bib18">Genaro et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Rees and Roberts, 1993</xref>; <xref ref-type="bibr" rid="bib52">Terenzi et al., 1992</xref>; <xref ref-type="bibr" rid="bib51">Terenzi et al., 1991</xref>; <xref ref-type="bibr" rid="bib55">Villarreal et al., 2004</xref>). So far, it remains to be determined whether the PV+ neurons of the APT may participate to these descending pathways and modulate nociception at the spinal level.</p><p>In conclusion, our data point to Cav3.2 channels as a prime target for developing innovative analgesic pharmacology that will not only act at the peripheral level but also in central structures. Furthermore, they highlight the need to study the functional expression of channels in specific neuronal population to decipher the complex pain processing that occurs in the central nervous system.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Lead contact and materials availability</title><p>For each figure, data are included in the figure – source data files.</p><p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Régis C Lambert (regis.lambert@sorbonne-universite.fr).</p></sec><sec id="s4-2"><title>Experimental model and subject details</title><sec id="s4-2-1"><title>Animals</title><p>Cav3.2<sup>eGFP-flox</sup> (Cacna1h<sup>tm1.1(epH)Ebou</sup>/J) knock in (KI) mouse line was obtained from Dr. E. Bourinet (<xref ref-type="bibr" rid="bib17">François et al., 2015</xref>). Briefly, these mice express the ecliptic GFP (eGFP) in an extracellular loop of the Cav3.2 T channel. LoxP sites were inserted allowing the deletion of the Cav3.2-eGFP coding sequence by <italic>cre</italic>-recombinase (<italic>cre</italic>). Mouse lines of PV <italic>cre</italic> (B6.129P2-Pvalb<sup>tm1(cre)Arbr</sup>/J, stock #017320) mice expressing <italic>cre</italic> under the PV promoter, Ai14 (B6.Cg-Gt(ROSA)26Sor<sup>tm14(CAG-tdTomato)Hze</sup>/J, stock #007914) mice expressing tdTomato reporter, and Ai32 (B6.Cg-Gt(ROSA)26Sor<sup>tm32(CAG-COPC4*H134E/EYPF)Hze/</sup>J, stock #024109) mice expressing channelrhodopsin-2 (ChR2)-eYFP were purchased from Jackson lab. PV-Cre:Ai14 and PV-Cre:Ai32 mice were obtained by crossing female PV-Cre with male Ai14 or Ai32 mice, respectively. Animals were housed in groups of 2–5 per cage, with a 12/12 hr light/dark cycle in a pathogen-free facility maintained at 22–24°C, and access to food and water ad libitum. All procedures complied with the ethical guidelines of the Federation for Laboratory Animal Science Associations (FELASA) and with the approval of the French National Consultative Ethics Committee for health and life sciences (authorization number: 17958).</p></sec></sec><sec id="s4-3"><title>Method details</title><sec id="s4-3-1"><title>Immunocytochemistry and imaging</title><p>Mice (P28–P217) were anesthetized with 2% isoflurane, injected with a lethal dose of pentobarbital (150 mg/kg) and transcardiacally perfused with a 4°C solution of Artificial Cerebro-Spinal Fluid (ACSF), oxygenated with a mixture 95% O<sub>2</sub>/5% CO<sub>2</sub>, containing (in mM): 125 NaCl, 2.5 KCl, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 26 NaHCO<sub>3</sub>, 25 glucose. The brains were then rapidly extracted from the skull and incubated in a solution of paraformaldehyde diluted to 4% in phosphate buffer solution (PBS: phosphate buffer saline) for postfixation overnight at 4°C. 40-μm-thick coronal slices were cut using a vibratome (Leica VT1000S) in PBS.</p><p>All immunohistochemical staining were performed at room temperature. The slices were rinsed three times in Tris buffer saline (TBS, containing 50 mM Tris Base and 150 mM NaCl) at pH 8.4, then incubated in TBS solution supplemented with 0.05% Tween 20, 0.2% Triton X-100 and 10% Donkey Serum (TBSTD) for 1h30. The slices were then incubated with the primary antibodies (see Table) in TBSTD solution overnight, rinsed three times with TBS, incubated with secondary antibodies (see Table) in TBSTD for 2 hr and rinsed again three times before mounting between slide and coverslip in Fluoromount.</p><p>Whole slice images were acquired by epifluorescence microscopy under a macroscope (Axio Zoom, V16 Zeiss). Mosaics were made at ×200 magnification and processed with the ZEN software (Zeiss). The images used to study the coexpressions were acquired with confocal microscopy (Leica TCS SP5) at ×20 and ×63 objectives.</p></sec><sec id="s4-3-2"><title>SNI model</title><p>SNI or sham surgeries were performed as previously described (<xref ref-type="bibr" rid="bib12">Decosterd and Woolf, 2000</xref>) under ketamine–xylasine anesthesia (100 and 10 mg/kg, respectively) on male and female KI mice (10–15 weeks old). The left thigh to be operated on was slightly elevated and an incision of about 1 cm is made between the hip and the knee. The muscles enclosing the sciatic nerve compartment were moved apart with a round-ended bent scissor. The common peroneal and tibial branches of the sciatic nerve were exposed and tightly ligated with 6-0 silk suture. A fragment of nerve was transected distally to the ligation. The sural branch was left intact. The muscles were then put back in apposition and the skin was sutured using 4-0 Vicryl (Ethicon). Mice were then kept in a 37°C warming chamber until recovery from anesthesia, before being returned to their homecages. In sham surgery, the sciatic nerve branches were exposed, but not injured.</p></sec><sec id="s4-3-3"><title>Surgery and preparation for in vivo electrophysiological recordings</title><p>Mice (males; 8–12 weeks; sham mice <italic>n</italic> = 5; SNI mice <italic>n</italic> = 4) were anesthetized with isoflurane vaporized in a mixture of oxygen and air (4% for induction, 1.5–2% during surgery). Body temperature was maintained at 37°C via a servo-controlled heating blanket and a rectal thermometer (Harvard Apparatus, Holliston, MA). Bupivacaine (subcutaneous) was administered in the regions to be incised 15 min prior to the first incision. Mice were placed in a stereotaxic apparatus and a craniotomy was made directly above the anterior pretectal nucleus (−2.7 to −3.0 mm A/P, 1–1.2 mm M/L). To minimize damage during electrode penetration, the dura was resected and the exposed surface was coated with a layer of silicon oil. After electrodes placement, isoflurane was decreased to 0.8–1%. If the animals presented any sign of discomfort, the percentage of isoflurane was increased. Electrodes were lowered to the anterior pretectal nucleus based on readings from the micromanipulator (depths: 2600–2900 µm).</p></sec><sec id="s4-3-4"><title>In vivo electrophysiological recordings</title><p>Animals underwent the procedure 2–3 weeks after SNI or sham surgeries. Recordings of units were obtained using quartz-insulated platinum/tungsten (90%/10%) tetrodes (~1–2 MOhm, Thomas Recording). Before insertion, the rear of the tetrodes was painted with fluorescent 1,1′-dioctadecyl- 3,3,3′,3′-tetramethyl indocarbocyanine perchlorate (DiI, 10% in ethanol, Invitrogen). As this dye is a lipophilic neuronal tracer, it allowed assessment of the recording depth. One to three tetrodes were guided independently at 1-µm resolution through a five-channel concentric microdrive head (Head05-cube-305-305-b, Thomas Recording GmbH) with 305 µm interelectrode spacing.</p><p>Raw signals were filtered (600–6000 Hz; Neuralynx recording systems), amplified (5000×), digitized at 33,657 Hz, and stored with stimulus markers (Cheetah 5 software; Neuralynx). Waveforms crossing set thresholds (300–500 μV) were captured via the A/D card and analyzed offline. At the end of the experiment, mice were injected with a lethal dose of euthasol, and the brains were removed and placed in a 4% paraformaldehyde solution for 48 hr. The brains were then transferred and stored in PBS (0.1 M). Sections (280 μm thick) containing the anterior pretectal nucleus were cut with a vibratome (Leica VT1000S). Sections were then mounted in Fluoromount medium.</p></sec><sec id="s4-3-5"><title>Slice preparation</title><p>Investigation of PV+ neuron firing properties were performed on slices obtained from 13 male and 11 female PV-Cre:AI14 mice (P23–P123, median: P35). Comparison of PV+ neuron-bursting properties between SNI and sham-operated mice were performed on slices prepared 22–41 days after surgery (Sham: six mice, four males, two females, P87–P103; SNI: seven mice, five males, two females, P91–P110). Mice were anesthetized with isoflurane before decapitation. The brain was carefully removed and placed for a few minutes into a 4–8°C bicarbonate-buffered saline (BBS) solution containing (in mM): 125 NaCl, 2.5 KCl, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 26 NaHCO<sub>3</sub>, and 25 glucose (osmolarity: 305 mOsm; pH 7.3 after equilibration with 95% O<sub>2</sub> and 5% CO<sub>2</sub>). Coronal slices (250 µm) were then cut using a vibratome (Campden Instruments 700 SMZ2). The slicing procedure was performed in an ice-cold solution containing (in mM): 130 potassium gluconate, 15 KCl, 2 ethylene glycol-bis(ß-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 20 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 25 glucose, 1 CaCl<sub>2</sub>, and 6 MgCl<sub>2</sub> (304 mOsm, pH 7.4 after equilibration). Slices were then transferred for few minutes to a solution containing (in mM): 225 <sc>D</sc>-mannitol, 2.5 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 25 NaHCO<sub>3</sub>, 25 glucose, 1 CaCl<sub>2</sub>, and 6 MgCl<sub>2</sub> (310 mOsm, 4–8°C, oxygenated with 95% O<sub>2</sub>/5% CO<sub>2</sub>), and finally stored for the rest of the experiment at 32°C in oxygenated BBS. For all recordings, slices were continuously perfused with oxygenated BBS at 32°C.</p></sec><sec id="s4-3-6"><title>In vitro whole-cell patch-clamp recording</title><p>Brain slices were screened for fluorescent neurons using a filter set that allowed us to detect dt-tomato fluorescence. Neurons were visualized and patched with borosilicate pipettes (resistance 3–5 MOhm). The intracellular solution contained (in mM): 140 potassium gluconate, 3 MgCl<sub>2</sub>, 10 HEPES, 0.2 EGTA, and 4 disodium ATP (pH 7.3; 300 mOsm). For some experiments, biocytin (2 mg/ml) was added to the intracellular solution. Patch-clamp electrodes were connected to a AxoPatch 200B (Axon Instrument) amplifier. Protocols and acquisitions were controlled by the Clampex software (Molecular Devices). The membrane potentials were filtered by a 4-pole Bessel filter set at a corner frequency of 2 kHz and digitized online at a sampling rate of 20 kHz. The access resistance was 10–20 MOhm and was monitored throughout the experiment. Data were discarded if the access resistance changed by more than 15% during the experiment. Current clamp recordings were performed in the continuous presence of 10 µM CNQX and 1 µM SR95531 to suppress spontaneous synaptic activities. Only one neuron per slice was recorded in experiments requiring the application of T-channel antagonists.</p><p>At the end of the recordings, slices containing biocytin-filled neurons were fixed overnight by immersion in paraformaldehyde (4% in PBS 1 M) and then washed with 1 M PBS. After incubating the slices with Triton (0.2% in PBS 1 M) for 1 hr, biocytin-filled neurons were revealed using Streptavidin Alexa Fluor 488 (1:1000; 3 hr in dark; Invitrogen). Slices were then washed in PBS (1 hr) before being mounted on cover slides.</p></sec><sec id="s4-3-7"><title>Cytoplasm harvesting and scRT-PCR</title><p>For scRT-PCR, recordings were performed on slices obtained from four male and two female PV-Cre:AI14 mice (P15–P21). At the end of the whole-cell recording, lasting less than 15 min, the cytoplasmic content was aspirated in the recording pipette. The pipette’s content was expelled into a test tube and reverse transcription was performed in a final volume of 10 µl, as described previously (<xref ref-type="bibr" rid="bib30">Lambolez et al., 1992</xref>). The scRT-PCR protocol was designed to probe simultaneously the expression of Cav3 isotypes, GAD65/67, VGluT2, and PV. Two-step amplification was performed essentially as described (<xref ref-type="bibr" rid="bib8">Cauli et al., 1997</xref>; <xref ref-type="bibr" rid="bib13">Devienne et al., 2018</xref>). Briefly, cDNAs present in the 10 µl reverse transcription reaction were first amplified simultaneously using all external primer pairs listed in the Key Ressources Table. Taq polymerase and 20 pmol of each primer were added to the buffer supplied by the manufacturer (final volume, 100 µl), and 20 cycles (94°C, 30 s; 60°C, 30 s; 72°C, 35 s) of PCR were run. Second rounds of PCR were performed using 1 µl of the first PCR product as a template. In this second round, each cDNA was amplified individually using its specific nested primer pair (Key Ressources Table) by performing 35 PCR cycles (as described above). 10 µl of each individual PCR product were run on a 2% agarose gel stained with ethidium bromide using ФX174 digested by <italic>Hae</italic>III as a molecular weight marker.</p></sec><sec id="s4-3-8"><title>Virus stereotaxic injections</title><p>Male and female KI (6–8 weeks) were anesthetized with a ketamine–xylazine mixture (100 and 10 mg/kg, respectively) and placed on a heating pad. A vitamin B12 eye drop (Twelve TVM) was applied to the eyes and a subcutaneous injection of sterile saline solution (NaCl 0.9%) was performed to prevent dry eyes and dehydration, respectively. The surgical area was cleaned with ethanol and sanitized with an iodine solution (Vetedine). Lidocaine was administered subcutaneously at the incision site. Mice were placed on a stereotaxic apparatus and a craniotomy was performed over the area of interest. Saline solution was regularly applied to the skull.</p><p>Injection pipette was lowered to the APT coordinates (Bregma: −2.70 to −2.80 mm; Mediolateral: ±1.10 to 1.15 mm; Depth: −2.65 to −2.70 mm from the dura) and either, 1 μl of AAV8-hSyn-mCherry-Cre (4.9 × 10<sup>12</sup> ppm) or 1 μl of AAV8-hSyn-mCherry (4.6 × 10<sup>12</sup> ppm) were injected bilaterally with a graduated injection wheel (Narishige, 100 μl/rev) at a rate of 0.1–0.2 μl/min. Five to ten minutes after injection, the pipette was slowly raised. The wound edges were then put back in place and the skin sutured with Vicryl 4-0 thread (Ethicon) or surgical glue (Vetbond 3M). Mice were kept on a heating pad until recovery from anesthesia before being returned to their home cages.</p></sec><sec id="s4-3-9"><title>Behavioral tests</title><p>Two series of behavioral tests were conducted separately in two different laboratories by different experimenters in blinded condition. Results are presented independently in <xref ref-type="fig" rid="fig5">Figure 5</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>. Mechanical and cold sensitivity was tested in preventively injected KI and KO mice, as well as in therapeutically injected KI and KO SNI mice in Clermont-Ferrand. Mechanical sensitivity in preventively injected KI and KO mice was also assessed in Paris, along with locomotor tests. Both series of experiments yielded similar results, despite notable differences in the PWTs measured, which can be explained by the differences of experimental conditions.</p></sec><sec id="s4-3-10"><title>Mechanical sensitivity</title><p>Mechanical sensitivity was assessed using Von Frey method. Mice were habituated to the testing environment before baseline testing. On the day of behavior testing, mice were placed in compartments on an elevated grid to allow access to the paw. Different filaments, ranging from 0.02 to 1.4 g, were applied perpendicularly to the plantar surface of the operated paw. 50% PWT was determined using an adaptation of the up and down method (<xref ref-type="bibr" rid="bib9">Chaplan et al., 1994</xref>).</p></sec><sec id="s4-3-11"><title>Cold sensitivity</title><p>Cold sensitivity was assessed by immersing the operated paw in a 18°C water bath until withdrawal or shaking was observed. In order to avoid stressing mice that are manually tethered in a piece of tissue, they were habituated to the test for 3 days before the baseline test in room temperature water. The first two latencies measured with a difference of less than 2 s were averaged to obtain the pain withdrawal latency.</p></sec><sec id="s4-3-12"><title>Motor behaviors</title><p>Motor coordination assessments were performed using the rotarod test. Mice were placed on the rotarod device (Bioseb) during 3 min with an accelerating ramp of 4–6 rounds per min. The latency to fall was automatically measured. The test was performed three times for each day of measurement, with two baseline measurements and one measurement at the end of the neuropathic tests. Spontaneous locomotion was also estimated at the end of the neuropathic tests using the circular corridor test. Mice were placed in the cyclotron (IMetronic) in the dark. Four detectors located around the corridor allowed the measurement of the number of quarter turns performed by the animals during 2 hr.</p><p>In each mouse, immunolabeling of GFP was systematically performed at the end of the behavioral tests. Observation of mCherry and GFP expression allowed to control the localization/extend of the virus infection and the efficiency of Cav3.2 deletion in KO mice.</p></sec></sec><sec id="s4-4"><title>Quantification and statistical analysis</title><p>No statistical methods were used to predetermine sample sizes, which are comparable to many studies using similar techniques and animal models.</p><sec id="s4-4-1"><title>Imaging data analysis</title><p>Confocal images acquired for the evaluation of coexpression of Cav3.2-GFP, PV, and NeuN were processed using the Fiji/ImageJ software, with the Cell Counter plug-in for manual cell counts. Quantification of the co-labeling of GFP and NeuN were performed on three mice (two males, one female) by analyzing 11–18 images in 5–8 brain slices per mouse. Quantification of the co-labeling of GFP and PV were performed on three mice (two males, one female) by analyzing 10–12 images in 5–8 brain slices per mouse. Data are expressed as mean ± standard deviation.</p></sec><sec id="s4-4-2"><title>Electrophysiological data analysis</title><p>For in vivo data analysis, potential single units were first identified using automated clustering software utilizing peak and trough feature sets (KlustaKwik). These clusters were then examined manually for waveform shape (SpikeSort3D, Neuralynx). Upon examination of the interspike intervals, multiunit clusters were discarded.</p><p>Bursts consisted of an initial spike that was followed by one or more spikes at an interval equal to or less than 5 ms. Since we were interested in potentially T-type channel-mediated bursts, another exclusion criterion was added: bursts had to be preceded by a pause in the spiking activity of at least 50 ms. Bursts recorded in response to the 470 nm blue-light pulse used for PINP were not included in the calculation of the spiking activity.</p><p>For in vivo and in vitro experiments, each neuron was considered as an independent observation since the number of recorded units/cells varied considerably from one mouse to another (2–6 units per mouse in the case of in vivo experiments and 1–3 neurons in the case of in vitro experiments). The number of mice and the average number of recorded units/neurons per mouse are indicated in the ‘source data’ files for each experimental condition.</p><p>Quantification and statistical analysis of in vivo and in vitro data were performed with the Igor Pro v6 and Matlab 2019b softwares, respectively. Between conditions comparison was based on Wilcoxon rank-sum test (Mann–Whitney <italic>U</italic>-test) and Wilcoxon signed rank test for unpaired and paired datasets, respectively. Differences were considered significant if the p value was lower than 0.05. All data were presented as the means ± standard deviation.</p></sec><sec id="s4-4-3"><title>Behavioral data analysis</title><p>Behavioral data analysis and statistics were performed in R (version 4.1.0), using the RStudio software. Data normality was checked using the Shapiro–Wilks test and no normal distribution was found throughout the datasets.</p><p>For mechanical and cold sensitivity, the presence of statistical differences in treatment across the multiple time points was assessed within each group (male KO, female KO, male KI, female KI) using the nonparametric Friedman test. The existence of significant differences between the two baseline measurements was checked using a paired Wilcoxon signed rank test. As no significant difference was found between baseline measurements within each group, these values were averaged as a mean baseline value. Each measurement performed after SNI surgery was then compared to the mean baseline value with the paired Wilcoxon signed rank test. Global intergroup comparisons (KI vs. KO) were performed using the Kruskal–Wallis test. At each time point, significant differences between groups were further identified using the Wilcoxon rank-sum test.</p><p>For the Rotarod test, the existence of significant differences within each group in the latency to fall measured in baseline conditions and 21 days after SNI surgery was assessed using the Wilcoxon signed rank test. Intergroup comparison was performed using the Wilcoxon rank-sum test.</p><p>For the circular corridor test, intergroup comparison was performed using the Wilcoxon rank-sum test.</p><p>Differences were considered significant if the p value was lower than 0.05. All values are expressed as mean ± standard error to the mean.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Validation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Supervision, Validation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Validation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All procedures complied with the ethical guidelines of the Federation for Laboratory Animal Science Associations (FELASA) and with the approval of the French National Consultative Ethics Committee for health and life sciences (authorization number: 17958).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-79018-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by operating grants from the Agence Nationale de la Recherche (ANR Pain-T and 'Investissements d’Avenir' program I-Site CAP 20-25).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barthó</surname><given-names>P</given-names></name><name><surname>Freund</surname><given-names>TF</given-names></name><name><surname>Acsády</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Selective GABAergic innervation of thalamic nuclei from zona incerta</article-title><source>The European Journal of Neuroscience</source><volume>16</volume><fpage>999</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9568.2002.02157.x</pub-id><pub-id pub-id-type="pmid">12383229</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>DLH</given-names></name><name><surname>Woods</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Painful and painless channelopathies</article-title><source>The Lancet. Neurology</source><volume>13</volume><fpage>587</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70024-9</pub-id><pub-id pub-id-type="pmid">24813307</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokor</surname><given-names>H</given-names></name><name><surname>Frère</surname><given-names>SGA</given-names></name><name><surname>Eyre</surname><given-names>MD</given-names></name><name><surname>Slézia</surname><given-names>A</given-names></name><name><surname>Ulbert</surname><given-names>I</given-names></name><name><surname>Lüthi</surname><given-names>A</given-names></name><name><surname>Acsády</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Selective GABAergic control of higher-order thalamic relays</article-title><source>Neuron</source><volume>45</volume><fpage>929</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2005.01.048</pub-id><pub-id pub-id-type="pmid">15797553</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourinet</surname><given-names>E</given-names></name><name><surname>Alloui</surname><given-names>A</given-names></name><name><surname>Monteil</surname><given-names>A</given-names></name><name><surname>Barrère</surname><given-names>C</given-names></name><name><surname>Couette</surname><given-names>B</given-names></name><name><surname>Poirot</surname><given-names>O</given-names></name><name><surname>Pages</surname><given-names>A</given-names></name><name><surname>McRory</surname><given-names>J</given-names></name><name><surname>Snutch</surname><given-names>TP</given-names></name><name><surname>Eschalier</surname><given-names>A</given-names></name><name><surname>Nargeot</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception</article-title><source>The EMBO Journal</source><volume>24</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600515</pub-id><pub-id pub-id-type="pmid">15616581</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourinet</surname><given-names>E</given-names></name><name><surname>Francois</surname><given-names>A</given-names></name><name><surname>Laffray</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>T-Type calcium channels in neuropathic pain</article-title><source>Pain</source><volume>157 Suppl 1</volume><fpage>S15</fpage><lpage>S22</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000469</pub-id><pub-id pub-id-type="pmid">26785151</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabezas</surname><given-names>C</given-names></name><name><surname>Irinopoulou</surname><given-names>T</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Poncer</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular and functional characterization of GAD67-expressing, newborn granule cells in mouse dentate gyrus</article-title><source>Frontiers in Neural Circuits</source><volume>7</volume><elocation-id>60</elocation-id><pub-id pub-id-type="doi">10.3389/fncir.2013.00060</pub-id><pub-id pub-id-type="pmid">23565079</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Candelas</surname><given-names>M</given-names></name><name><surname>Reynders</surname><given-names>A</given-names></name><name><surname>Arango-Lievano</surname><given-names>M</given-names></name><name><surname>Neumayer</surname><given-names>C</given-names></name><name><surname>Fruquière</surname><given-names>A</given-names></name><name><surname>Demes</surname><given-names>E</given-names></name><name><surname>Hamid</surname><given-names>J</given-names></name><name><surname>Lemmers</surname><given-names>C</given-names></name><name><surname>Bernat</surname><given-names>C</given-names></name><name><surname>Monteil</surname><given-names>A</given-names></name><name><surname>Compan</surname><given-names>V</given-names></name><name><surname>Laffray</surname><given-names>S</given-names></name><name><surname>Inquimbert</surname><given-names>P</given-names></name><name><surname>Le Feuvre</surname><given-names>Y</given-names></name><name><surname>Zamponi</surname><given-names>GW</given-names></name><name><surname>Moqrich</surname><given-names>A</given-names></name><name><surname>Bourinet</surname><given-names>E</given-names></name><name><surname>Méry</surname><given-names>PF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cav3.2 T-type calcium channels shape electrical firing in mouse lamina II neurons</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>3112</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-39703-3</pub-id><pub-id pub-id-type="pmid">30816223</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Audinat</surname><given-names>E</given-names></name><name><surname>Lambolez</surname><given-names>B</given-names></name><name><surname>Angulo</surname><given-names>MC</given-names></name><name><surname>Ropert</surname><given-names>N</given-names></name><name><surname>Tsuzuki</surname><given-names>K</given-names></name><name><surname>Hestrin</surname><given-names>S</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Molecular and physiological diversity of cortical nonpyramidal cells</article-title><source>The Journal of Neuroscience</source><volume>17</volume><fpage>3894</fpage><lpage>3906</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.17-10-03894.1997</pub-id><pub-id pub-id-type="pmid">9133407</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaplan</surname><given-names>SR</given-names></name><name><surname>Bach</surname><given-names>FW</given-names></name><name><surname>Pogrel</surname><given-names>JW</given-names></name><name><surname>Chung</surname><given-names>JM</given-names></name><name><surname>Yaksh</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Quantitative assessment of tactile allodynia in the rat paw</article-title><source>Journal of Neuroscience Methods</source><volume>53</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/0165-0270(94)90144-9</pub-id><pub-id pub-id-type="pmid">7990513</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W-K</given-names></name><name><surname>Liu</surname><given-names>IY</given-names></name><name><surname>Chang</surname><given-names>Y-T</given-names></name><name><surname>Chen</surname><given-names>Y-C</given-names></name><name><surname>Chen</surname><given-names>C-C</given-names></name><name><surname>Yen</surname><given-names>C-T</given-names></name><name><surname>Shin</surname><given-names>H-S</given-names></name><name><surname>Chen</surname><given-names>C-C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ca (V) 3.2 T-type Ca2+ channel-dependent activation of ERK in paraventricular thalamus modulates acid-induced chronic muscle pain</article-title><source>The Journal of Neuroscience</source><volume>30</volume><fpage>10360</fpage><lpage>10368</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1041-10.2010</pub-id><pub-id pub-id-type="pmid">20685979</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Na</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Campbell</surname><given-names>KP</given-names></name><name><surname>Shin</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Attenuated pain responses in mice lacking Ca (V) 3.2 T-type channels</article-title><source>Genes, Brain, and Behavior</source><volume>6</volume><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1111/j.1601-183X.2006.00268.x</pub-id><pub-id pub-id-type="pmid">16939637</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decosterd</surname><given-names>I</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Spared nerve injury: an animal model of persistent peripheral neuropathic pain</article-title><source>Pain</source><volume>87</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(00)00276-1</pub-id><pub-id pub-id-type="pmid">10924808</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devienne</surname><given-names>G</given-names></name><name><surname>Le Gac</surname><given-names>B</given-names></name><name><surname>Piquet</surname><given-names>J</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Single cell multiplex reverse transcription polymerase chain reaction after patch-clamp</article-title><source>Journal of Visualized Experiments</source><volume>57627</volume><elocation-id>57627</elocation-id><pub-id pub-id-type="doi">10.3791/57627</pub-id><pub-id pub-id-type="pmid">29985318</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumenieu</surname><given-names>M</given-names></name><name><surname>Senkov</surname><given-names>O</given-names></name><name><surname>Mironov</surname><given-names>A</given-names></name><name><surname>Bourinet</surname><given-names>E</given-names></name><name><surname>Kreutz</surname><given-names>MR</given-names></name><name><surname>Dityatev</surname><given-names>A</given-names></name><name><surname>Heine</surname><given-names>M</given-names></name><name><surname>Bikbaev</surname><given-names>A</given-names></name><name><surname>Lopez-Rojas</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The low-threshold calcium channel cav3.2 mediates burst firing of mature dentate granule cells</article-title><source>Cerebral Cortex</source><volume>28</volume><fpage>2594</fpage><lpage>2609</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhy084</pub-id><pub-id pub-id-type="pmid">29790938</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Boustani</surname><given-names>S</given-names></name><name><surname>Sermet</surname><given-names>BS</given-names></name><name><surname>Foustoukos</surname><given-names>G</given-names></name><name><surname>Oram</surname><given-names>TB</given-names></name><name><surname>Yizhar</surname><given-names>O</given-names></name><name><surname>Petersen</surname><given-names>CCH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Anatomically and functionally distinct thalamocortical inputs to primary and secondary mouse whisker somatosensory cortices</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3342</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17087-7</pub-id><pub-id pub-id-type="pmid">32620835</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Férézou</surname><given-names>I</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name><name><surname>Hill</surname><given-names>EL</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name><name><surname>Hamel</surname><given-names>E</given-names></name><name><surname>Lambolez</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>5-Ht3 receptors mediate serotonergic fast synaptic excitation of neocortical vasoactive intestinal peptide/cholecystokinin interneurons</article-title><source>The Journal of Neuroscience</source><volume>22</volume><fpage>7389</fpage><lpage>7397</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-17-07389.2002</pub-id><pub-id pub-id-type="pmid">12196560</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>François</surname><given-names>A</given-names></name><name><surname>Schüetter</surname><given-names>N</given-names></name><name><surname>Laffray</surname><given-names>S</given-names></name><name><surname>Sanguesa</surname><given-names>J</given-names></name><name><surname>Pizzoccaro</surname><given-names>A</given-names></name><name><surname>Dubel</surname><given-names>S</given-names></name><name><surname>Mantilleri</surname><given-names>A</given-names></name><name><surname>Nargeot</surname><given-names>J</given-names></name><name><surname>Noël</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>JN</given-names></name><name><surname>Moqrich</surname><given-names>A</given-names></name><name><surname>Pongs</surname><given-names>O</given-names></name><name><surname>Bourinet</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The low-threshold calcium channel Cav3.2 determines low-threshold mechanoreceptor function</article-title><source>Cell Reports</source><volume>10</volume><fpage>370</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.12.042</pub-id><pub-id pub-id-type="pmid">25600872</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genaro</surname><given-names>K</given-names></name><name><surname>Fabris</surname><given-names>D</given-names></name><name><surname>Prado</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The antinociceptive effect of anterior pretectal nucleus stimulation is mediated by distinct neurotransmitter mechanisms in descending pain pathways</article-title><source>Brain Research Bulletin</source><volume>146</volume><fpage>164</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2019.01.003</pub-id><pub-id pub-id-type="pmid">30634015</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerke</surname><given-names>MB</given-names></name><name><surname>Duggan</surname><given-names>AW</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Siddall</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Thalamic neuronal activity in rats with mechanical allodynia following contusive spinal cord injury</article-title><source>Neuroscience</source><volume>117</volume><fpage>715</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/s0306-4522(02)00961-2</pub-id><pub-id pub-id-type="pmid">12617975</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giber</surname><given-names>K</given-names></name><name><surname>Slézia</surname><given-names>A</given-names></name><name><surname>Bokor</surname><given-names>H</given-names></name><name><surname>Bodor</surname><given-names>ÁL</given-names></name><name><surname>Ludányi</surname><given-names>A</given-names></name><name><surname>Katona</surname><given-names>I</given-names></name><name><surname>Acsády</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Heterogeneous output pathways link the anterior pretectal nucleus with the zona incerta and the thalamus in rat</article-title><source>The Journal of Comparative Neurology</source><volume>506</volume><fpage>122</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1002/cne.21545</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Keyser</surname><given-names>BM</given-names></name><name><surname>Tagmose</surname><given-names>TM</given-names></name><name><surname>Hansen</surname><given-names>JB</given-names></name><name><surname>Taylor</surname><given-names>JT</given-names></name><name><surname>Zhuang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Ragsdale</surname><given-names>DS</given-names></name><name><surname>Li</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Nnc 55-0396 [ (1S,2S) -2- (2- (N- [ (3-benzimidazol-2-yl) propyl ] -N-methylamino) ethyl) -6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride ]: a new selective inhibitor of T-type calcium channels</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>309</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1124/jpet.103.060814</pub-id><pub-id pub-id-type="pmid">14718587</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagodic</surname><given-names>MM</given-names></name><name><surname>Pathirathna</surname><given-names>S</given-names></name><name><surname>Joksovic</surname><given-names>PM</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Nelson</surname><given-names>MT</given-names></name><name><surname>Naik</surname><given-names>AK</given-names></name><name><surname>Su</surname><given-names>P</given-names></name><name><surname>Jevtovic-Todorovic</surname><given-names>V</given-names></name><name><surname>Todorovic</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve</article-title><source>Journal of Neurophysiology</source><volume>99</volume><fpage>3151</fpage><lpage>3156</lpage><pub-id pub-id-type="doi">10.1152/jn.01031.2007</pub-id><pub-id pub-id-type="pmid">18417624</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeanmonod</surname><given-names>D</given-names></name><name><surname>Magnin</surname><given-names>M</given-names></name><name><surname>Morel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Low-threshold calcium spike bursts in the human thalamus: common physiopathology for sensory, motor and limbic positive symptoms</article-title><source>Brain</source><volume>119 (Pt 2)</volume><fpage>363</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1093/brain/119.2.363</pub-id><pub-id pub-id-type="pmid">8800933</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>AF</given-names></name><name><surname>Sheets</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sex-specific disruption of distinct mpfc inhibitory neurons in spared-nerve injury model of neuropathic pain</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107729</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107729</pub-id><pub-id pub-id-type="pmid">32521254</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Gallopin</surname><given-names>T</given-names></name><name><surname>Lacroix</surname><given-names>A</given-names></name><name><surname>Plaisier</surname><given-names>F</given-names></name><name><surname>Piquet</surname><given-names>J</given-names></name><name><surname>Geoffroy</surname><given-names>H</given-names></name><name><surname>Hepp</surname><given-names>R</given-names></name><name><surname>Naudé</surname><given-names>J</given-names></name><name><surname>Le Gac</surname><given-names>B</given-names></name><name><surname>Egger</surname><given-names>R</given-names></name><name><surname>Lambolez</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name><name><surname>Staiger</surname><given-names>JF</given-names></name><name><surname>Imamura</surname><given-names>H</given-names></name><name><surname>Seino</surname><given-names>S</given-names></name><name><surname>Roeper</surname><given-names>J</given-names></name><name><surname>Cauli</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Lactate is an energy substrate for rodent cortical neurons and enhances their firing activity</article-title><source>eLife</source><volume>10</volume><elocation-id>e71424</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.71424</pub-id><pub-id pub-id-type="pmid">34766906</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerckhove</surname><given-names>N</given-names></name><name><surname>Mallet</surname><given-names>C</given-names></name><name><surname>François</surname><given-names>A</given-names></name><name><surname>Boudes</surname><given-names>M</given-names></name><name><surname>Chemin</surname><given-names>J</given-names></name><name><surname>Voets</surname><given-names>T</given-names></name><name><surname>Bourinet</surname><given-names>E</given-names></name><name><surname>Alloui</surname><given-names>A</given-names></name><name><surname>Eschalier</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ca (V) 3.2 calcium channels: the key protagonist in the supraspinal effect of paracetamol</article-title><source>PAIN</source><volume>155</volume><fpage>764</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2014.01.015</pub-id><pub-id pub-id-type="pmid">24447516</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>I</given-names></name><name><surname>Keum</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Jeong</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>McEnery</surname><given-names>MW</given-names></name><name><surname>Shin</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking alpha (1G) T-type Ca (2+) channels</article-title><source>Neuron</source><volume>31</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(01)00343-9</pub-id><pub-id pub-id-type="pmid">11498049</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>D</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Shin</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Thalamic control of visceral nociception mediated by T-type Ca2+ channels</article-title><source>Science</source><volume>302</volume><fpage>117</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1126/science.1088886</pub-id><pub-id pub-id-type="pmid">14526084</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>RC</given-names></name><name><surname>Bessaïh</surname><given-names>T</given-names></name><name><surname>Crunelli</surname><given-names>V</given-names></name><name><surname>Leresche</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The many faces of T-type calcium channels</article-title><source>Pflugers Archiv</source><volume>466</volume><fpage>415</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1007/s00424-013-1353-6</pub-id><pub-id pub-id-type="pmid">24043572</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambolez</surname><given-names>B</given-names></name><name><surname>Audinat</surname><given-names>E</given-names></name><name><surname>Bochet</surname><given-names>P</given-names></name><name><surname>Crépel</surname><given-names>F</given-names></name><name><surname>Rossier</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Ampa receptor subunits expressed by single Purkinje cells</article-title><source>Neuron</source><volume>9</volume><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(92)90164-9</pub-id><pub-id pub-id-type="pmid">1323310</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavallée</surname><given-names>P</given-names></name><name><surname>Urbain</surname><given-names>N</given-names></name><name><surname>Dufresne</surname><given-names>C</given-names></name><name><surname>Bokor</surname><given-names>H</given-names></name><name><surname>Acsády</surname><given-names>L</given-names></name><name><surname>Deschênes</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Feedforward inhibitory control of sensory information in higher-order thalamic nuclei</article-title><source>The Journal of Neuroscience</source><volume>25</volume><fpage>7489</fpage><lpage>7498</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2301-05.2005</pub-id><pub-id pub-id-type="pmid">16107636</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Gomora</surname><given-names>JC</given-names></name><name><surname>Cribbs</surname><given-names>LL</given-names></name><name><surname>Perez-Reyes</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Nickel block of three cloned T-type calcium channels: low concentrations selectively block alpha1H</article-title><source>Biophysical Journal</source><volume>77</volume><fpage>3034</fpage><lpage>3042</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(99)77134-1</pub-id><pub-id pub-id-type="pmid">10585925</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Latchoumane</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><name><surname>Saud</surname><given-names>ZA</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>N</given-names></name><name><surname>Cheong</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Choi</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name><name><surname>Shin</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rebound burst firing in the reticular thalamus is not essential for pharmacological absence seizures in mice</article-title><source>PNAS</source><volume>111</volume><fpage>11828</fpage><lpage>11833</lpage><pub-id pub-id-type="doi">10.1073/pnas.1408609111</pub-id><pub-id pub-id-type="pmid">25071191</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenz</surname><given-names>FA</given-names></name><name><surname>Kwan</surname><given-names>HC</given-names></name><name><surname>Dostrovsky</surname><given-names>JO</given-names></name><name><surname>Tasker</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Characteristics of the bursting pattern of action potentials that occurs in the thalamus of patients with central pain</article-title><source>Brain Research</source><volume>496</volume><fpage>357</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(89)91088-3</pub-id><pub-id pub-id-type="pmid">2804648</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>SQ</given-names></name><name><surname>Hromádka</surname><given-names>T</given-names></name><name><surname>Znamenskiy</surname><given-names>P</given-names></name><name><surname>Zador</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Pinp: a new method of tagging neuronal populations for identification during in vivo electrophysiological recording</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e6099</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006099</pub-id><pub-id pub-id-type="pmid">19584920</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llinás</surname><given-names>RR</given-names></name><name><surname>Ribary</surname><given-names>U</given-names></name><name><surname>Jeanmonod</surname><given-names>D</given-names></name><name><surname>Kronberg</surname><given-names>E</given-names></name><name><surname>Mitra</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Thalamocortical dysrhythmia: A neurological and neuropsychiatric syndrome characterized by magnetoencephalography</article-title><source>PNAS</source><volume>96</volume><fpage>15222</fpage><lpage>15227</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.26.15222</pub-id><pub-id pub-id-type="pmid">10611366</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masri</surname><given-names>R</given-names></name><name><surname>Quiton</surname><given-names>RL</given-names></name><name><surname>Lucas</surname><given-names>JM</given-names></name><name><surname>Murray</surname><given-names>PD</given-names></name><name><surname>Thompson</surname><given-names>SM</given-names></name><name><surname>Keller</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Zona incerta: a role in central pain</article-title><source>Journal of Neurophysiology</source><volume>102</volume><fpage>181</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1152/jn.00152.2009</pub-id><pub-id pub-id-type="pmid">19403748</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messinger</surname><given-names>RB</given-names></name><name><surname>Naik</surname><given-names>AK</given-names></name><name><surname>Jagodic</surname><given-names>MM</given-names></name><name><surname>Nelson</surname><given-names>MT</given-names></name><name><surname>Lee</surname><given-names>WY</given-names></name><name><surname>Choe</surname><given-names>WJ</given-names></name><name><surname>Orestes</surname><given-names>P</given-names></name><name><surname>Latham</surname><given-names>JR</given-names></name><name><surname>Todorovic</surname><given-names>SM</given-names></name><name><surname>Jevtovic-Todorovic</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>In vivo silencing of the Ca (V) 3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy</article-title><source>Pain</source><volume>145</volume><fpage>184</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2009.06.012</pub-id><pub-id pub-id-type="pmid">19577366</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>PD</given-names></name><name><surname>Masri</surname><given-names>R</given-names></name><name><surname>Keller</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Abnormal anterior pretectal nucleus activity contributes to central pain syndrome</article-title><source>Journal of Neurophysiology</source><volume>103</volume><fpage>3044</fpage><lpage>3053</lpage><pub-id pub-id-type="doi">10.1152/jn.01070.2009</pub-id><pub-id pub-id-type="pmid">20357063</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrini</surname><given-names>C</given-names></name><name><surname>Lecci</surname><given-names>S</given-names></name><name><surname>Lüthi</surname><given-names>A</given-names></name><name><surname>Astori</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Suppression of sleep spindle rhythmogenesis in mice with deletion of Cav3.2 and Cav3.3 T-type Ca (2+) channels</article-title><source>Sleep</source><volume>39</volume><fpage>875</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.5665/sleep.5646</pub-id><pub-id pub-id-type="pmid">26612388</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prado</surname><given-names>WA</given-names></name><name><surname>Roberts</surname><given-names>MHT</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>An assessment of the antinociceptive and aversive effects of stimulating identified sites in the rat brain</article-title><source>Brain Research</source><volume>340</volume><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(85)90917-5</pub-id><pub-id pub-id-type="pmid">4027651</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>H</given-names></name><name><surname>Roberts</surname><given-names>MHT</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>The anterior pretectal nucleus: a proposed role in sensory processing</article-title><source>PAIN</source><volume>53</volume><fpage>121</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(93)90072-W</pub-id><pub-id pub-id-type="pmid">8336983</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>H</given-names></name><name><surname>Terenzi</surname><given-names>MG</given-names></name><name><surname>Roberts</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Anterior pretectal nucleus facilitation of superficial dorsal horn neurones and modulation of deafferentation pain in the rat</article-title><source>The Journal of Physiology</source><volume>489 (Pt 1)</volume><fpage>159</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1995.sp021038</pub-id><pub-id pub-id-type="pmid">8583399</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>MHT</given-names></name><name><surname>Rees</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>The antinociceptive effects of stimulating the pretectal nucleus of the rat</article-title><source>PAIN</source><volume>25</volume><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(86)90011-4</pub-id><pub-id pub-id-type="pmid">3714289</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossaneis</surname><given-names>AC</given-names></name><name><surname>Genaro</surname><given-names>K</given-names></name><name><surname>Dias</surname><given-names>QM</given-names></name><name><surname>Guethe</surname><given-names>LM</given-names></name><name><surname>Fais</surname><given-names>RS</given-names></name><name><surname>Del Bel</surname><given-names>EA</given-names></name><name><surname>Prado</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Descending mechanisms activated by the anterior pretectal nucleus initiate but do not maintain neuropathic pain in rats</article-title><source>European Journal of Pain</source><volume>19</volume><fpage>1148</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1002/ejp.638</pub-id><pub-id pub-id-type="pmid">25487357</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossaneis</surname><given-names>AC</given-names></name><name><surname>Prado</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The ventral portion of the anterior pretectal nucleus controls descending mechanisms that initiate neuropathic pain in rats</article-title><source>Clinical and Experimental Pharmacology &amp; Physiology</source><volume>42</volume><fpage>704</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1111/1440-1681.12391</pub-id><pub-id pub-id-type="pmid">25809943</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schäfer</surname><given-names>S</given-names></name><name><surname>Ferioli</surname><given-names>S</given-names></name><name><surname>Hofmann</surname><given-names>T</given-names></name><name><surname>Zierler</surname><given-names>S</given-names></name><name><surname>Gudermann</surname><given-names>T</given-names></name><name><surname>Chubanov</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mibefradil represents a new class of benzimidazole TRPM7 channel agonists</article-title><source>Pflügers Archiv - European Journal of Physiology</source><volume>468</volume><fpage>623</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1007/s00424-015-1772-7</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>FY</given-names></name><name><surname>Chen</surname><given-names>ZY</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>LQ</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>ZJ</given-names></name><name><surname>Xie</surname><given-names>WL</given-names></name><name><surname>Wang</surname><given-names>YW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Alleviation of neuropathic pain by regulating T-type calcium channels in rat anterior cingulate cortex</article-title><source>Molecular Pain</source><volume>11</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/s12990-015-0008-3</pub-id><pub-id pub-id-type="pmid">25885031</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>Y</given-names></name><name><surname>Okubo</surname><given-names>K</given-names></name><name><surname>Maeda</surname><given-names>Y</given-names></name><name><surname>Sekiguchi</surname><given-names>F</given-names></name><name><surname>Mitani</surname><given-names>K</given-names></name><name><surname>Nishikawa</surname><given-names>H</given-names></name><name><surname>Kawabata</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Upregulation of Ca (V) 3.2 T-type calcium channels targeted by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain</article-title><source>Pain</source><volume>150</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2010.04.022</pub-id><pub-id pub-id-type="pmid">20546998</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley</surname><given-names>EM</given-names></name><name><surname>Cribbs</surname><given-names>LL</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><name><surname>Perez-Reyes</surname><given-names>E</given-names></name><name><surname>Bayliss</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels</article-title><source>The Journal of Neuroscience</source><volume>19</volume><fpage>1895</fpage><lpage>1911</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.19-06-01895.1999</pub-id><pub-id pub-id-type="pmid">10066243</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terenzi</surname><given-names>MG</given-names></name><name><surname>Rees</surname><given-names>H</given-names></name><name><surname>Morgan</surname><given-names>SJS</given-names></name><name><surname>Foster</surname><given-names>GA</given-names></name><name><surname>Roberts</surname><given-names>MHT</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>The antinociception evoked by anterior pretectal nucleus stimulation is partially dependent upon ventrolateral medullary neurones</article-title><source>PAIN</source><volume>47</volume><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(91)90209-G</pub-id><pub-id pub-id-type="pmid">1762819</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terenzi</surname><given-names>MG</given-names></name><name><surname>Rees</surname><given-names>H</given-names></name><name><surname>Roberts</surname><given-names>MHT</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The pontine parabrachial region mediates some of the descending inhibitory effects of stimulating the anterior pretectal nucleus</article-title><source>Brain Research</source><volume>594</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(92)91127-z</pub-id><pub-id pub-id-type="pmid">1450946</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tricoire</surname><given-names>L</given-names></name><name><surname>Pelkey</surname><given-names>KA</given-names></name><name><surname>Erkkila</surname><given-names>BE</given-names></name><name><surname>Jeffries</surname><given-names>BW</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>McBain</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A blueprint for the spatiotemporal origins of mouse hippocampal interneuron diversity</article-title><source>The Journal of Neuroscience</source><volume>31</volume><fpage>10948</fpage><lpage>10970</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0323-11.2011</pub-id><pub-id pub-id-type="pmid">21795545</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villarreal</surname><given-names>CF</given-names></name><name><surname>Del Bel</surname><given-names>EA</given-names></name><name><surname>Prado</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Involvement of the anterior pretectal nucleus in the control of persistent pain: a behavioral and c-fos expression study in the rat</article-title><source>Pain</source><volume>103</volume><fpage>163</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/s0304-3959(02)00449-9</pub-id><pub-id pub-id-type="pmid">12749971</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villarreal</surname><given-names>C.F</given-names></name><name><surname>Kina</surname><given-names>VAV</given-names></name><name><surname>Prado</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Participation of brainstem nuclei in the pronociceptive effect of lesion or neural block of the anterior pretectal nucleus in a rat model of incisional pain</article-title><source>Neuropharmacology</source><volume>47</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.03.002</pub-id><pub-id pub-id-type="pmid">15165839</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>HR</given-names></name><name><surname>Lee</surname><given-names>JI</given-names></name><name><surname>Lenz</surname><given-names>FA</given-names></name><name><surname>Schwartz</surname><given-names>A</given-names></name><name><surname>Vierck</surname><given-names>C</given-names></name><name><surname>Rowland</surname><given-names>L</given-names></name><name><surname>Dougherty</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Functional plasticity in primate somatosensory thalamus following chronic lesion of the ventral lateral spinal cord</article-title><source>Neuroscience</source><volume>101</volume><fpage>393</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/s0306-4522(00)00368-7</pub-id><pub-id pub-id-type="pmid">11074162</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background<break/>(<italic>Mus musculus</italic>, male and female)</td><td align="left" valign="bottom">Cav3.2-eGFPflox</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25600872/">25600872</ext-link><break/>(<xref ref-type="bibr" rid="bib17">François et al., 2015</xref>)</td><td align="left" valign="bottom">Cacna1h<sup>tm1.1(epH)Ebo</sup>/J</td><td align="left" valign="bottom">KI mice with two <italic>loxP</italic> site-flanked <break/>ecliptic-GFP tag into exon 6 of <break/>the <italic>Cacna1h</italic> gene</td></tr><tr><td align="left" valign="bottom">Strain, strain background<break/>(<italic>Mus musculus</italic>, female)</td><td align="left" valign="bottom">PV-Cre</td><td align="left" valign="bottom">Jackson lab</td><td align="left" valign="bottom">B6.129P2-<break/>Pvalb-<sup>tm1(cre)Arbr</sup>/J</td><td align="left" valign="bottom">Cre recombinase expression <break/>in <italic>Pvalb</italic>-expressing cells</td></tr><tr><td align="left" valign="bottom">Strain, strain background<break/>(<italic>Mus musculus</italic>, male)</td><td align="left" valign="bottom">Ai14</td><td align="left" valign="bottom">Jackson lab</td><td align="left" valign="bottom">B6.Cg-Gt(ROSA)<break/>26Sor-<sup>tm14(CAG-tdTomato)Hze</sup>/J</td><td align="left" valign="bottom">Cre-dependent expression <break/>of the red fluorescent protein <break/>variant (tdTomato)</td></tr><tr><td align="left" valign="bottom">Strain, strain background<break/>(<italic>Mus musculus</italic>, male)</td><td align="left" valign="bottom">Ai32</td><td align="left" valign="bottom">Jackson lab</td><td align="left" valign="bottom">B6.Cg-Gt(ROSA)<break/>26Sor<sup>tm32(CAG-COP4*H134R/EYFP)Hze</sup>/J</td><td align="left" valign="bottom">Cre-dependent expression of the <break/>ChR2(H134R)-EYFP</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Pvalb</italic> external sense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21795545/">21795545</ext-link><break/>(<xref ref-type="bibr" rid="bib53">Tricoire et al., 2011</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCCTGAAGAAAAAGAACCCG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Pvalb</italic> external antisense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21795545/">21795545</ext-link><break/>(<xref ref-type="bibr" rid="bib53">Tricoire et al., 2011</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AATCTTGCCGTCCCCATCCT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Pvalb</italic> internal sense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21795545/">21795545</ext-link><break/>(<xref ref-type="bibr" rid="bib53">Tricoire et al., 2011</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CGGATGAGGTGAAGAAGGTGT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Pvalb</italic> internal antisense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21795545/">21795545</ext-link><break/>(<xref ref-type="bibr" rid="bib53">Tricoire et al., 2011</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCCCCATCCTTGTCTCCAGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Gad2</italic> external sense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34766906/">34766906</ext-link><break/>(<xref ref-type="bibr" rid="bib25">Karagiannis et al., 2021</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCAAAAGTTCACGGGCGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Gad2</italic> external antisense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34766906/">34766906</ext-link><break/>(<xref ref-type="bibr" rid="bib25">Karagiannis et al., 2021</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTGAGCAGTATCGCAGCCCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Gad2</italic> internal sense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34766906/">34766906</ext-link><break/>(<xref ref-type="bibr" rid="bib25">Karagiannis et al., 2021</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CACCTGCGACCAAAAACCCT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Gad2</italic> internal antisense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12196560/">12196560</ext-link><break/>(<xref ref-type="bibr" rid="bib16">Férézou et al., 2002</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GATTTTGCGGTTGGTCTGCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Gad1</italic> external sense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23565079/">23565079</ext-link><break/>(<xref ref-type="bibr" rid="bib6">Cabezas et al., 2013</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TACGGGGTTCGCA<break/>CAGGTC CGGGCGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Gad1</italic> external antisense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23565079/">23565079</ext-link><break/>(<xref ref-type="bibr" rid="bib6">Cabezas et al., 2013</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCCAGGCAGCATCCACAT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Gad1</italic> internal sense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23565079/">23565079</ext-link><break/>(<xref ref-type="bibr" rid="bib6">Cabezas et al., 2013</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCCAGAAGTGAAGACAAAAGGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Gad1</italic> internal antisense</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23565079/">23565079</ext-link><break/>(<xref ref-type="bibr" rid="bib6">Cabezas et al., 2013</xref>)</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AATGCTCCGTAAACAGTCGTGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Slc17a6</italic> external sense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TGGAGAAGAAGCAGGACAACC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Slc17a6</italic> external antisense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTGAGCAGTATCGCAGCCCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Slc17a6</italic> internal sense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TGACAGAGGACGGTAAGCCCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Slc17a6</italic> internal antisense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCATCCCCACGGTCTCGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1g</italic> external sense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CACCGATGTCACTGCCCAAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1g</italic> external antisense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GGCTCTCCTGACCCTCTCCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1g</italic> internal sense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCTCTCGCCGCACCAGTA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1g</italic> internal antisense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CTTGGGCTCCTACGCTTCAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1h</italic> external sense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TACCAGACAGAGGAGGGCGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1h</italic> external antisense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CTATCACCACCAGGCACAGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1h</italic> internal sense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CATTCATCTGCTCCTCACGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1h</italic> internal antisense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCCCACAATGATGAGGAGGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1i</italic> external sense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTCCCCCTCCATCCCCTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1i</italic> external antisense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CAATGAAGAAGTCCAAGCGGTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1i</italic> internal sense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTTGCCTTCTTCTGCCTGCG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse <italic>Cacna1i</italic> internal antisense</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCCCCGAGGTAGCACTTCTT</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>AAV</italic>)</td><td align="left" valign="bottom">AAV8-hSyn-mCherry-Cre</td><td align="left" valign="bottom">UNC Vector Core</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>AAV</italic>)</td><td align="left" valign="bottom">AAV8-hSyn-mCherry</td><td align="left" valign="bottom">UNC Vector Core</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFP<break/>(chicken polyclonal)</td><td align="left" valign="bottom">Life Technologies</td><td align="left" valign="bottom">A10262</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFP<break/>(rabit polyclonal)</td><td align="left" valign="bottom">Chromotek</td><td align="left" valign="bottom">PABG1</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Parvalbumin (mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">P3088</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-NeuN (rabbit polyclonal)</td><td align="left" valign="bottom">Merck Millipore</td><td align="left" valign="bottom">ABN78</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-chicken-Alexa Fluor 488 (goat polyclonal)</td><td align="left" valign="bottom">Life Technologies</td><td align="left" valign="bottom">A11039</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-chicken-Alexa Fluor 488 (donkey polyclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">SAB4600031</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabit-Alexa Fluor 647 (goat polyclonal)</td><td align="left" valign="bottom">Life Technologies</td><td align="left" valign="bottom">A21244</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse-Alexa Fluor 488 (goat polyclonal)</td><td align="left" valign="bottom">Life Technologies</td><td align="left" valign="bottom">A11001</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabit-Cyanine Cy3 (donkey polyclonal)</td><td align="left" valign="bottom">Jackson ImmunoResearch <break/>Europe</td><td align="char" char="hyphen" valign="bottom">711-165-1525</td><td align="char" char="." valign="bottom">1:2000</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Isoflurane</td><td align="left" valign="bottom">Iso-Vet</td><td align="left" valign="bottom">Cat# 3248850; <break/>GTIN: 18904026625157</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Buprenorphine (Buprecare)</td><td align="left" valign="bottom">Axience</td><td align="left" valign="bottom">GTIN: 03760087151893</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Pentobarbital (Euthasol Vet)</td><td align="left" valign="bottom">Dechra</td><td align="left" valign="bottom">GTIN: 08718469445110</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ketamine</td><td align="left" valign="bottom">Imalgene 1000</td><td align="left" valign="bottom">GTIN: 03661103003199</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Xylazine (Rompun)</td><td align="left" valign="bottom">Bayer</td><td align="left" valign="bottom">GTIN: 04007221032311</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bupivacaine</td><td align="left" valign="bottom">Henry Schein</td><td align="left" valign="bottom">Cat# 054879</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Twelve TVM Eye Support Drops</td><td align="left" valign="bottom">TVM UK Animal Health</td><td align="left" valign="bottom">GTIN: 03700454507502</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Vetedine</td><td align="left" valign="bottom">Vetoquinol</td><td align="left" valign="bottom">GTIN: 03605870001385</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NaCl</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# S6191; <break/>CAS: 7647-14-5</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">KCl</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 60128; <break/>CAS: 7447-40-7</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CaCl<sub>2</sub></td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# C3881; <break/>CAS: 10035-04-8</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MgCl<sub>2</sub></td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# M2670; <break/>CAS: 7791-18-6</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NaH<sub>2</sub>PO<sub>4</sub></td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# S5011; <break/>CAS: 7558-80-7</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NaHCO<sub>3</sub></td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 31437; <break/>CAS: 144-55-8</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Glucose</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 49159; <break/>CAS: 14431-43-7</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Potassium gluconate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# G4500; <break/>CAS: 299-27-4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">EGTA</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# E3889; <break/>CAS: 67-42-5</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HEPES</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# H3375; <break/>CAS: 7365-45-9</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Disodium ATP</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A7699; <break/>CAS: 34369-07-8</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Biocytin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# B4261; <break/>CAS: 576-19-2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom"><sc>D</sc>-Mannitol</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# M9647; <break/>CAS: 69-65-8</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium Pyruvate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# P2256; <break/>CAS: 113-24-6</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Kynurenic acid</td><td align="left" valign="bottom">Hello Bio</td><td align="left" valign="bottom">Cat# HB0363; <break/>CAS: 2439-02-3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Paraformaldehyde in 0.1 M phosphate buffer saline</td><td align="left" valign="bottom">Electron Microscopy Sciences</td><td align="left" valign="bottom">Cat# 15710; <break/>CAS: 30525-89-4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Trizma</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# T1503; <break/>CAS: 77-86-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium azide</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# S2002; <break/>CAS: 26628-22-8</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphate buffer saline</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# D1408</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Triton X-100</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# T8787; <break/>CAS: 9002-93-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fluoromount Aquaous Mounting Medium</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# F4680</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Donkey serum</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# D9663</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Streptavidin-<break/>Rhodamine-RedX</td><td align="left" valign="bottom">Jackson ImmunoResearch <break/>Europe</td><td align="left" valign="bottom">Cat# 016-290-084</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DiI, 10% in ethanol</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# V22885</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CNQX</td><td align="left" valign="bottom">Hello bio</td><td align="left" valign="bottom">Cat# HB02057; CAS: 479347-85-8</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SR95531 hydrobromide</td><td align="left" valign="bottom">Hello bio</td><td align="left" valign="bottom">Cat# HB0901; <break/>CAS: 104104-50-9</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TTX</td><td align="left" valign="bottom">Latoxan</td><td align="left" valign="bottom">Cat# L8503; <break/>CAS: 4368-28-9</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nickel chloride hydrate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 364304; <break/>CAS: 69098-15-3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TTA-P2</td><td align="left" valign="bottom">Alomone labs</td><td align="left" valign="bottom">Cat# T-155; <break/>CAS: 918430-49-6</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Taq DNA Polymerase</td><td align="left" valign="bottom">Qiagen</td><td align="char" char="." valign="bottom">201205</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RNasin Ribonuclease Inhibitors</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">N2511</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SuperScript II Reverse Transcriptase</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# 18064014</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Pclamp V 10.2</td><td align="left" valign="bottom">Molecular Devices</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.moleculardevices.com/">https://www.moleculardevices.com/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Matlab 2019b</td><td align="left" valign="bottom">MathWorks</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://fr.mathworks.com/">https://fr.mathworks.com/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Igor Pro V6</td><td align="left" valign="bottom">Wavemetrics</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.wavemetrics.com">https://www.wavemetrics.com</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Cheetah V 5</td><td align="left" valign="bottom">Neuralynx</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://neuralynx.com/software/cheetah">https://neuralynx.com/software/cheetah</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">KlustaKwik</td><td align="left" valign="bottom">Neuralynx</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://neuralynx.com/software/cheetah">https://neuralynx.com/software/cheetah</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SpikeSort3D V 2</td><td align="left" valign="bottom">Neuralynx</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://neuralynx.com/software/cheetah">https://neuralynx.com/software/cheetah</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Fiji/ImageJ</td><td align="left" valign="bottom">NIH</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/download.html">https://imagej.nih.gov/ij/download.html</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Rstudio</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.rstudio.com/">https://www.rstudio.com/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R version 4.1.0 (2021-05-18)</td><td align="left" valign="bottom">Camp Pontanezen – The R Foundation for Statistical Computing</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Quartz-insulated platinum/tungsten (90%/10%) tetrodes</td><td align="left" valign="bottom">Thomas Recording GmbH</td><td align="left" valign="bottom">Cat# AN000259</td><td align="left" valign="bottom">See ‘In vivo electrophysiological <break/>recordings’ in the Method Details</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Optical fibers</td><td align="left" valign="bottom">Thomas Recording GmbH</td><td align="left" valign="bottom">Cat# AN000514</td><td align="left" valign="bottom">Optical fiber used to deliver 470-nm <break/>blue-light pulse for Photo-assisted <break/>Identification of Neuronal Population</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Borosilicate glass capillaries</td><td align="left" valign="bottom">Hilgenberg</td><td align="left" valign="bottom">Cat# 1409250</td><td align="left" valign="bottom">See ‘In vitro whole-cell patch-clamp <break/>recording’ in the Method Details</td></tr><tr><td align="left" valign="bottom">Other</td><td align="char" char="ndash" valign="bottom">4-0 Vicryl</td><td align="left" valign="bottom">Ethicon</td><td align="left" valign="bottom">ref JV397</td><td align="left" valign="bottom">See ‘Virus stereotaxic injections’ in <break/>the Method Details</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79018.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Westbrook</surname><given-names>Gary L</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/009avj582</institution-id><institution>Oregon Health &amp; Science University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.04.27.489708" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.27.489708"/></front-stub><body><p>The manuscript shows an important role for Cav2.3 channels in SNI-mediated allodynia and the firing properties of PV-expressing APT neurons. Mechanisms that underlie adaptations in chronic pain models are extremely important for the development of novel therapeutics for chronic pain and this could be a significant contribution in that regard.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79018.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Westbrook</surname><given-names>Gary L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/009avj582</institution-id><institution>Oregon Health &amp; Science University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Ingram</surname><given-names>Susan L</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02hh7en24</institution-id><institution>University of Colorado Denver</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Todorovic</surname><given-names>Slobodan</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wmf1y16</institution-id><institution>University of Colorado Anschutz Medical Campus</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.27.489708">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.04.27.489708v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Centrally expressed Cav3.2 T-type calcium channel is critical for the initiation and maintenance of neuropathic pain&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Gary Westbrook as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Susan Ingram (Reviewer #1); Slobodan Todorovic (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. Although there is considerable support for the findings, there is consensus among the reviewers that it is essential to provide direct evidence that the SNI increase in firing involved Cav3.2 channels that you characterized. Specifically, it is important to show that Ni-sensitive currents and rebound bursts in APT neurons are altered by SNI and that they are diminished/attenuated by APT KO. Addressing this question would examine the behavior in the SNI model in the KO, or in vitro recordings from the KO should be added.</p><p>2. The above is the major concern required in a revision. But, in addition, appropriate statistics that use a nested design for multiple cells in animals should be used for Figure 2.</p><p>3. Please also attend to other issues raised in the original comments of the reviewers below.</p><p>We think these studies can be performed within two months (the usual period allowed for <italic>eLife</italic> revisions) and look forward to seeing a suitably revised version. Please note, however, that if you are not able to demonstrate that Cav3.2 channels indeed contribute to SNI-induced changes in burst firing, it will not be publishable in <italic>eLife</italic>.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The recommendation is to provide details of the statistics used and rationale for analysis of multiple observations in single animals. It is not clear if they are treated as independent observations or corrected for in the analyses.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. Figure 1, does SNI alter the expression of Cav3.2 and the overlap between Cav3.2 and PV in APT?</p><p>2. Figure 2, please clarify whether light-evoked bursts are included when calculating the mean firing rate? If yes, what's the mean firing rate in the absence of evoked bursts, and is it different between naïve and SNI mice? Does SNI alter mean firing and/or evoked bursts in the ipsilateral APT? Sham mice should be used as the control of SNI.</p><p>3. Figure 3, are the amplitude of Ni-sensitive current, the number of spikes in rebound burst and the spike-current relationship altered by SNI? Are they attenuated in APT-KO mice after sham/SNI?</p><p>4. Figure 4B-C, in SNI mice that receive AAV-Cre, does blocking peripheral/spinal Cav3.2 further attenuate/normalize mechanical allodynia?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79018.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The recommendation is to provide details of the statistics used and rationale for analysis of multiple observations in single animals. It is not clear if they are treated as independent observations or corrected for in the analyses.</p></disp-quote><p>We considered each unit as an independent observation. We did so since the number of recorded PV+-units per animal (identified with the PINP method) was small and varied greatly between animals, from 2 to 6 units. We are not aware of statistical methods using a nested design for multiple cells in animals that could be used in such condition.</p><p>Since the measured variables did not follow normal distributions, we performed unpaired comparison with the Wilcoxon sum rank test. This is now stated in the section ‘quantification and statistical analysis’ (page 22, line 680). P-values are now included in the figures and the result section when appropriate.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. Figure 1, does SNI alter the expression of Cav3.2 and the overlap between Cav3.2 and PV in APT?</p></disp-quote><p>We did not perform a systematic comparison of the Cav3.2 and PV colocalization between control and SNI mice but we did not observe a change in the number of GFP-expressing neurons per slice after SNI.</p><disp-quote content-type="editor-comment"><p>2. Figure 2, please clarify whether light-evoked bursts are included when calculating the mean firing rate? If yes, what's the mean firing rate in the absence of evoked bursts, and is it different between naïve and SNI mice? Does SNI alter mean firing and/or evoked bursts in the ipsilateral APT? Sham mice should be used as the control of SNI.</p></disp-quote><p>Light-evoked bursts were not included when calculating the mean firing rate. We apologize for this omission in the description of the analysis protocol. This point is now specified in the Materials and methods section (page 22, line 677).</p><p>We did not record in the ipsilateral APT.</p><p>We fully agree that we should have used sham animals in first instance and we accordingly performed a new set of experiments. Now, all control animals underwent sham surgery. Statistically significant differences between sham operated and SNI animals were observed similarly to what was previously reported for the naïve/SNI comparison (see new Figure 2 and Results section page 3, lines 98-116).</p><disp-quote content-type="editor-comment"><p>3. Figure 3, are the amplitude of Ni-sensitive current, the number of spikes in rebound burst and the spike-current relationship altered by SNI? Are they attenuated in APT-KO mice after sham/SNI?</p></disp-quote><p>We could not directly assess the impact of SNI on Cav3.2 current amplitude for technical reasons. Indeed, at the beginning of our study, we tried to record low-threshold calcium currents in APT neurons. Although we choose to record these currents in very young mice (P12 -14) to minimize the space clamp problem, it was clearly impossible to clamp the membrane potential even at this age when the dendritic arborization is not fully mature. Many experimental and theoretical studies have shown that in non-spherical cells, voltage-dependent currents, such as Cav3, are severely distorted due to the lack of space clamp (see for example Bar-Yehuda and Korngreen J. neurophysiol 2008). Recording Ni<sup>2+</sup> sensitive currents in sham versus SNI mice, approximately 100 days old, cannot be performed with the minimal accuracy required for rigorous comparison.</p><p>Therefore, we performed a new set of experiments by recording rebound burst responses in PV+ APT neurons in sham and SNI mice. By comparing the rebound bursts, we observed that the distribution of the maximum number of spikes in the rebound bursts is shifted to larger values in SNI compared to sham mice. To evaluate whether Cav3.2 channels are indeed responsible for this increase in bursts, we applied 100<italic>µM</italic> Ni<sup>2+</sup> and observed that this difference in distribution disappeared. These results, which clearly show a Cav3.2 related enhance rebound burst in APT neurons after SNI are now presented page 4, line 150-158, in the new figure 4 (panel D) and outlined as one of the main result of the present study at the end of the introduction (page 2, line 71).</p><p>We could not perform similar experiments in APT-KO mice. Given that Cav3.2-expressing neurons represent 20% of the APT neuron population, comparing bursting activity in KI and APT-KO mice after sham/SNI would require identification of this specific subpopulation in living tissue, which is clearly not possible in APT-KO mice. As far as KI mice are concerned, although a GFP tag is attached to the Cav3.2 channels in the Cav3.2<sup>eGFP-flox</sup> knock-in, its fluorescence is not detectable without antibody preventing direct identification in living tissue (François et al., 2015).</p><disp-quote content-type="editor-comment"><p>4. Figure 4B-C, in SNI mice that receive AAV-Cre, does blocking peripheral/spinal Cav3.2 further attenuate/normalize mechanical allodynia?</p></disp-quote><p>At the peripheral level, deletion of Cav3.2 in a subset of sensory neurons altered light-touch perception and noxious mechanical, cold and chemical sensation (François et al., Cell Reports, 2015). In the SNI model, such deletion also induced a marked reduction in the mechanical allodynia similar to that reported here. To date, no data are available regarding the effect of a specific Cav3.2 KO at the spinal level. Indeed, the multiple sites where Cav3.2 seems to play a crucial role in chronic pain open very interesting question about the respective roles of centrally versus peripherally expressed Cav3.2 channels in allodynia. However, such studies would require a large number of experimental investigations that are well beyond the scope of the present work.</p></body></sub-article></article>